CUMULATIVE
SUPPLEMENT 10
OCT'99



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGMENT AND SERVICES

1999

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

S.O.

S.O.

SUBSCRIBE NOW!

Available in March 2000

New 20th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION
2000

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

Cumulative Supplement 10

OCTOBER 1999

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

CUMULATIVE SUPPLEMENT 10
OCTOBER 1999

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 19th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 19th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 20th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)	ASTRA ZENECA LP (ASTRA ZENECA)
PENEDERM INC (PENEDERM)	BERTEK PHARMACEUTICALS (BERTEK PHARMS)
SANOFI PHARMACEUTICALS INC (SANOFI)	SANOFI SYNTHELABO INC (SANOFI SYNTHELABO)

1.3 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.4 AVAILABILITY OF THE EDITION

The 19th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $90.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 19th annual edition of the 1998 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder/orange/19bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at
http://www.fda.gov/cder/orange/supplement/patents.pdf.

The current listing of the Orphan Product Designations and Approvals is available at
http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1998) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1998	MAR 1999	JUN 1999	SEP 1999
DRUG PRODUCTS LISTED	9923	9975	10009	9939
SINGLE SOURCE	2504 (25.2%)	2520 (25.3%)	2523 (25.2%)	2557 (25.7%)
MULTISOURCE	7308 (73.6%)	7344 (73.6%)	7375 (73.7%)	7271 (73.2%)
THERAPEUTICALLY EQUIVALENT	6934 (69.9%)	6969 (69.9%)	7012 (70.1%)	6923 (69.7%)
NOT THERAPEUTICALLY EQUIVALENT	374 (3.8%)	375 (3.8%)	363 (3.6%)	348 (3.5%)
EXCEPTIONS[1]	111 (1.1%)	111 (1.1%)	111 (1.1%)	111 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	10	3	5	13
NUMBER OF APPLICANTS	563	570	568	572

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACETAMINOPHEN; BUTALBITAL; CAPFEINE

CAPSULE; ORAL

	BUTALBITAL, ACETAMINOPHEN, CAFFEINE		
AB	GRAHAM DM	**325MG;50MG;40MG**	**N88758 001** **MAR 27, 1985**
	@ MALLINCKRODT	325MG;50MG;40MG	N88758 001 MAR 27, 1985
	FEMCET		
AB	MALLINCKRODT	**325MG;50MG;40MG**	**N89102 001** **JUN 19, 1985**
	@	325MG;50MG;40MG	N89102 001 JUN 19, 1985
	TRIAD		
AB	MALLINCKRODT	**325MG;50MG;40MG**	**N89023 001** **JUN 19, 1985**
	@	325MG;50MG;40MG	N89023 001 JUN 19, 1985

TABLET; ORAL

	BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE		
AB	WEST WARD	**500MG;50MG;40MG**	**N40336 001** AUG 18, 1999

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

	ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODONE BITARTRATE		
+	MIKART	712.8MG;60MG;32MG	N40316 001 APR 28, 1999

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

	ALLAY		
AA	NORTON HN	**500MG;5MG**	**N89907 001** **JAN 13, 1989**
AA	ZENITH GOLDLINE	**500MG;5MG**	**N89907 001** JAN 13, 1989
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN		
AA	MALLINCKRODT	**500MG;5MG**	**N88956 001** JUL 19, 1985
	ZYDONE		
AA	MALLINCKRODT	**500MG;5MG**	**N88956 001** **JUL 19, 1985**

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

	OXYCODONE AND ACETAMINOPHEN		
AA	DURAMED	**500MG;5MG**	**N40289 001** MAR 16, 1999

TABLET; ORAL

	OXYCODONE AND ACETAMINOPHEN		
AA	AMIDE PHARM	**325MG;5MG**	**N40203 001** MAR 15, 1999
	PERCOCET		
	ENDO PARMS	**325MG;2.5MG**	**N40330 001** **JUN 25, 1999**
AA	ENDO PHARMS	**325MG;5MG**	**N40330 002** JUN 25, 1999
+		325MG;2.5MG	N40330 001 JUN 25, 1999
+		500MG;7.5MG	N40341 001 JUL 26, 1999
+		650MG;10MG	N40341 002 JUL 26, 1999

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	PROPACET 100		
AB	TEVA	**650MG;100MG**	**N70107 001** **JUN 12, 1985**
	@	650MG;100MG	N70107 001 JUN 12, 1985

ACITRETIN

CAPSULE; ORAL

	SORIATANE		
	HLR	10MG	N19821 001 OCT 28, 1996
+		25MG	N19821 002 OCT 28, 1996
	ROCHE	10MG	N19821 001 OCT 28, 1996
+		25MG	N19821 002 OCT 28, 1996

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR
AB STASON 200MG N75090 001 JAN 26, 1999

TABLET; ORAL
ACYCLOVIR
AB CARLSBAD 400MG N75382 001 APR 30, 1999
AB 800MG N75382 002 APR 30, 1999

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR
AP ABBOTT EQ 50MG BASE/ML N75114 001 JUL 26, 1999

ACYCLOVIR SODIUM
AP + AM PHARM PARTNERS EQ 50MG BASE/ML N74930 001 MAY 13, 1998 >ADD> >ADD>
+ EQ 50MG BASE/ML N74930 001 MAY 13, 1998 >DLT> >DLT>
AP MERIDIAN MEDCL TECHN EQ 50MG BASE/ML N75065 001 FEB 25, 1999 >ADD> >ADD> >ADD>

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL
AB MEDEVA 0.09MG/INH N72273 001 AUG 14, 1996
AB MEDEVA PHARMS MA 0.09MG/INH N72273 001 AUG 14, 1996

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE
AN HI TECH PHARMA EQ 0.083% BASE N75063 001 FEB 09, 1999

SYRUP; ORAL
ALBUTEROL SULFATE
AA UDL EQ 2MG BASE/5ML N75262 001 MAR 30, 1999

ALBUTEROL SULFATE

SYRUP; ORAL
VENTOLIN
AA + GLAXO WELLCOME EQ 2MG BASE/5ML N19621 001 JUN 10, 1987
@ EQ 2MG BASE/5ML N19621 001 JUN 10, 1987

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION
ALCOHOL 5% IN DEXTROSE 5% IN WATER
AP BAXTER HLTHCARE 5ML/100ML;5GM/100ML N83256 001
@ 5ML/100ML;5GM/100ML N83256 001

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
ALFENTA
AP + AKORN EQ 0.5MG BASE/ML N19353 001 DEC 29, 1986
+ EQ 0.5MG BASE/ML N19353 001 DEC 29, 1986
ALFENTANIL
AP ABBOTT EQ 0.5MG BASE/ML N75221 001 OCT 28, 1999

ALITRETINOIN

GEL; TOPICAL
PANRETIN
+ LIGAND EQ 0.1% BASE N20886 001 FEB 02, 1999

ALLOPURINOL

TABLET; ORAL
ZYLOPRIM
AB FARO PHARMS 100MG N16084 001
AB + 300MG N16084 002
AB GLAXO WELLCOME 100MG N16084 001
AB + 300MG N16084 002

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

	ALOPRIM		
+	CATALYTICA PHARMS	EQ 500MG BASE/VIAL	N20298 001 MAY 17, 1996
	ZYLOPRIM		
+	CATALYTICA PHARMS	EQ 500MG BASE/VIAL	N20298 001 MAY 17, 1996

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION

	CERNEVIT-12		
+	BAXTER HLTHCARE	11.2 IU/VIAL;125MG/VIAL;60 UGM/VIAL; 200 IU/VIAL;5.5MG/VIAL;414 UGM/VIAL; 46MG/VIAL;17.25MG/VIAL;4.53MG/VIAL; 4.14MG/VIAL;3.51MG/VIAL; 3,500 IU/VIAL	N20924 001 APR 06, 1999

ALPRAZOLAM

CONCENTRATE; ORAL

	ALPRAZOLAM		
	ROXANE	1MG/ML	N74312 001 OCT 31, 1993
+		1MG/ML	N74312 001 OCT 31, 1993

SOLUTION; ORAL

	ALPRAZOLAM		
	ROXANE	0.5MG/5ML	N74314 001 OCT 31, 1993
+		0.5MG/5ML	N74314 001 OCT 31, 1993

TABLET; ORAL

	ALPRAZOLAM		
AB	ALPHAPHARM	**2MG**	**N74046 004** MAY 07, 1997

ALPROSTADIL

INJECTABLE; INJECTION

	ALPROSTADIL		
AP	GENSIA SICOR PHARMS	**0.5MG/ML**	**N75196 001** APR 30, 1999

AMCINONIDE

CREAM; TOPICAL

	CYCLOCORT		
@	FUJISAWA HLTHCARE	0.025%	N18116 001
+		0.1%	N18116 002
	LEDERLE	0.025%	N18116 001
+		0.1%	N18116 002

LOTION; TOPICAL

	CYCLOCORT		
+	FUJISAWA HLTHCARE	0.1%	N19729 001 JUN 13, 1988
+	LEDERLE	0.1%	N19729 001 JUN 13, 1988

OINTMENT; TOPICAL

	CYCLOCORT		
+	FUJISAWA HLTHCARE	0.1%	N18498 001
+	WYETH AYERST	0.1%	N18498 001

AMIFOSTINE

INJECTABLE; INJECTION

	ETHYOL		
	US BIOSCIENCE	375MG/VIAL	N20221 002 SEP 10, 1999

AMINO ACIDS

INJECTABLE; INJECTION

	AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE		
	FRESENIUS KABI	5.2%	N18901 001 APR 06, 1984
	PHARMACIA AND UPJOHN	5.2%	N18901 001 APR 06, 1984
	NEOPHAM 6.4%		
@	FRESENIUS KABI	6.4%	N18792 001 JAN 17, 1984

AMINO ACIDS

INJECTABLE; INJECTION

NEOPHAM 6.4%			
@ PHARMACIA AND UPJOHN	6.4%		N18792 001 JAN 17, 1984
NOVAMINE 11.4%			
FRESENIUS KABI	11.4%		N17957 003 AUG 09, 1982
PHARMACIA AND UPJOHN	11.4%		N17957 003 AUG 09, 1982
NOVAMINE 15%			
FRESENIUS KABI	15%		N17957 004 NOV 28, 1986
PHARMACIA AND UPJOHN	15%		N17957 004 NOV 28, 1986
NOVAMINE 8.5%			
@ FRESENIUS KABI	8.5%		N17957 002 AUG 09, 1982
@ PHARMACIA AND UPJOHN	8.5%		N17957 002 AUG 09, 1982

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%			
@ FRESENIUS KABI	8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML		N17957 001
@ PHARMACIA AND UPJOHN	8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML		N17957 001

AMINOPHYLLINE

INJECTABLE; INJECTION

	AMINOPHYLLINE		
AP	SMITH AND NEPHEW	**25MG/ML**	**N88749 001 MAY 30, 1985**
	@	25MG/ML	N88749 001 MAY 30, 1985

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

	AMIODARONE HCL		
AB	ALPHAPHARM	200MG	N75188 001 FEB 24, 1999

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

	AMIODARONE HCL		
AB	NOVOPHARM	**200MG**	**N74895 001 APR 16, 1999**

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION

	AMITRIPTYLINE HCL		
AP	STERIS	**10MG/ML**	**N85594 001**
	@	10MG/ML	N85594 001
	ELAVIL		
AP	+ ZENECA	**10MG/ML**	**N12704 001**
	+	10MG/ML	N12704 001

TABLET; ORAL

	AMITRIPTYLINE HCL		
BP	COPLEY PHARM	10MG	N88421 001 APR 30, 1984
BP		25MG	N88422 001 APR 30, 1984
BP		50MG	N88423 001 APR 30, 1984
BP		75MG	N88424 001 APR 30, 1984
BP		100MG	N88425 001 APR 30, 1984
BP		150MG	N88426 001 APR 30, 1984
	@	10MG	N88421 001 APR 30, 1984
	@	25MG	N88422 001 APR 30, 1984
	@	50MG	N88423 001 APR 30, 1984
	@	75MG	N88424 001 APR 30, 1984
	@	100MG	N88425 001 APR 30, 1984
	@	150MG	N88426 001 APR 30, 1984
	ENDEP		
AB	ROCHE	**10MG**	**N83639 001**
AB		**25MG**	**N83639 002**
AB		**50MG**	**N83639 003**
AB		**75MG**	**N83639 004**

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	ENDEP			
AB	ROCHE	100MG	N83639 005	
@		10MG	N83639 001	
@		25MG	N83639 002	
@		50MG	N83639 003	
@		75MG	N83639 004	
@		100MG	N83639 005	

AMOXICILLIN

CAPSULE; ORAL

	AMOXICILLIN			
AB	RANBAXY	250MG	N65016 001	APR 08, 1999
AB		500MG	N65016 002	APR 08, 1999

POWDER FOR RECONSTITUTION; ORAL

	AMOXIL			
	SMITHKLINE BEECHAM	200MG/5ML	N50760 001	APR 15, 1999
+		400MG/5ML	N50760 002	APR 15, 1999

TABLET, CHEWABLE; ORAL

	AMOXIL			
	SMITHKLINE BEECHAM	200MG	N50761 001	APR 15, 1999
+		400MG	N50761 002	APR 15, 1999

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

	AMPHOTEC			
+	ALZA	50MG/VIAL	N50729 001	NOV 22, 1996
+		100MG/VIAL	N50729 002	NOV 22, 1996
+	SEQUUS	50MG/VIAL	N50729 001	NOV 22, 1996
+		100MG/VIAL	N50729 002	NOV 22, 1996

AMPRENAVIR

CAPSULE; ORAL

	AGENERASE			
	GLAXO WELLCOME	50MG	N21007 001	APR 15, 1999
+		150MG	N21007 002	APR 15, 1999

SOLUTION; ORAL

	AGENERASE			
+	GLAXO WELLCOME	15MG/ML	N21039 001	APR 15, 1999

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

	KABIVITE PED F + W KIT			
+	FRESENIUS KABI	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A	N20176 001	DEC 29, 1993
+	PHARMACIA AND UPJOHN	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A	N20176 001	DEC 29, 1993

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE			
AB	ENDO PHARMS	325MG;50MG;40MG;30MG	N75351 001	MAR 05, 1999

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB	STEVENS J	**385MG;30MG;25MG**	**N74988 001** APR 30, 1999
AB		**770MG;60MG;50MG**	**N74988 002** APR 30, 1999

ASTEMIZOLE

TABLET; ORAL

HISMANAL

+	JANSSEN	10MG	N19402 001 DEC 29, 1988

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	APOTHECON	**50MG**	**N73317 001** MAR 20, 1992
AB		**100MG**	**N73318 001** MAR 20, 1992
@		50MG	N73317 001 MAR 20, 1992
@		100MG	N73318 001 MAR 20, 1992
	MYLAN	25MG	N73457 002 APR 26, 1999

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

AA	PHARMERAL	**0.025MG;2.5MG**	**N85035 001**
AA	R AND S PHARMA	**0.025MG;2.5MG**	**N85035 001**

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

AA	ZENITH GOLDLINE	**0.025MG;2.5MG**	**N86727 001**
@		0.025MG;2.5MG	N86727 001

AZATHIOPRINE

TABLET; ORAL

AZATHIOPRINE

AB	APPLIED ANAL	**50MG**	**N75252 001** JUN 07, 1999

IMURAN

AB	+ FARO PHARMS	**50MG**	**N16324 001**
@		25MG	N16324 002
AB	+ GLAXO WELLCOME	**50MG**	**N16324 001**
@		25MG	N16324 002

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

IMURAN

AP	+ FARO PHARMS	**EQ 100MG BASE/VIAL**	**N17391 001**
AP	+ GLAXO WELLCOME	**EQ 100MG BASE/VIAL**	**N17391 001**

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

POWDER FOR RECONSTITUTION, TABLET; ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK

+	PFIZER	EQ 1GM BASE,N/A;N/A, EQ 100MG BASE	N50762 001 DEC 18, 1998
@		EQ 1GM BASE,N/A;N/A, EQ 100MG BASE	N50762 001 DEC 18, 1998

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

AT	+ ALTANA	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N60731 002**
@		400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N60731 002
AT	PHARMADERM	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N62166 002**
+		400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62166 002

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL
CORZIDE

APOTHECON	5MG;40MG	N18647 001	
		MAY 25, 1983	
+	5MG;80MG	N18647 002	
		MAY 25, 1983	
BRISTOL MYERS SQUIBB	5MG;40MG	N18647 001	
		MAY 25, 1983	
+	5MG;80MG	N18647 002	
		MAY 25, 1983	

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
PRE-PEN

+ BAYER	60 UMOLAR	N50114 001	> DLT >
			> DLT >
+ HOLLISTER STIER LABS	60 UMOLAR	N50114 001	> ADD >
			> ADD >

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

	> ADD >			
	> ADD >			
AB	> ADD >	ALTANA	EQ 0.05% BASE	**N75373 001**
	> ADD >			JUN 22, 1999
	> ADD >			
	> ADD >			

BETAMETHASONE VALERATE

AEROSOL; TOPICAL
LUXIQ

+	CONNETICS	EQ 0.12% BASE	N20934 001
			FEB 28, 1999

BETAXOLOL HYDROCHLORIDE

TABLET; ORAL
BETAXOLOL HCL

> ADD >				
> ADD >	AB	AMIDE PHARM	10MG	**N75541 001**
> ADD >				OCT 22, 1999
> ADD >	AB		20MG	**N75541 002**
> ADD >				OCT 22, 1999

KERLONE

> ADD >	AB	LOREX	10MG	**N19507 001**
> ADD >				OCT 27, 1989

BETAXOLOL HYDROCHLORIDE

TABLET; ORAL
KERLONE

	AB	+ LOREX	20MG	**N19507 002**
				OCT 27, 1989
> ADD >				
> DLT >			10MG	N19507 001
> DLT >				OCT 27, 1989
> DLT >		+	20MG	N19507 002
> DLT >				OCT 27, 1989

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

> DLT >	AP	ASTRA PHARMS	50MG/ML	**N71153 001**
> DLT >				AUG 10, 1987
> ADD >		@ ASTRAZENECA	50MG/ML	N71153 001
> ADD >				AUG 10, 1987

BUDESONIDE

SPRAY, METERED; NASAL
RHINOCORT

> ADD >	ASTRAZENECA	0.032MG/INH	N20746 001
> ADD >			OCT 01, 1999
> ADD >	+	0.064MG/INH	N20746 002
> ADD >			OCT 01, 1999

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN

+ GLAXO WELLCOME	50MG	N20358 001
		OCT 04, 1996
+	100MG	N20358 002
		OCT 04, 1996
+	150MG	N20358 003
		OCT 04, 1996

WELLBUTRIN SR

+ GLAXO WELLCOME	50MG	N20358 001
		OCT 04, 1996
+	100MG	N20358 002
		OCT 04, 1996
+	150MG	N20358 003
		OCT 04, 1996

BUSULFAN

INJECTABLE; INJECTION
BUSULFEX
+ ORPHAN MEDCL 6MG/ML N20954 001 FEB 04, 1999

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT
+ SYNTEX 2% N19215 001 NOV 25, 1985
@ 2% N19215 001 NOV 25, 1985

FEMSTAT ONE
+ KV PHARM 2% N19881 001 FEB 07, 1997
+ SYNTEX 2% N19881 001 FEB 07, 1997

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL
CAFCIT
+ OPR DEVELOP LP EQ 10MG BASE/ML N20793 001 SEP 21, 1999

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

> DLT >
> DLT >
> DLT >
> DLT >

SOLUTION; IRRIGATION
ENDOSOL EXTRA
> ADD >
> ADD >
> ADD >
> ADD >
AT AKORN 0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML N20079 001 NOV 27, 1991
AT ALLERGAN 0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML N20079 001 NOV 27, 1991

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N18271 001
@ 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N18271 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML N18269 002 JAN 17, 1983
@ 35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML N18269 002 JAN 17, 1983

CALFACTANT

INJECTABLE; INJECTION
INFASURF PRESERVATIVE FREE
+ ONY 35MG/ML N20521 001 JUL 01, 1998

SUSPENSION; INTRATRACHEAL
INFASURF PRESERVATIVE FREE
+ ONY 35MG/ML N20521 001 JUL 01, 1998

CAPECITABINE

TABLET; ORAL
XELODA
HLR 150MG N20896 001 APR 30, 1998
ROCHE 150MG N20896 001 APR 30, 1998

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB		BAKER NORTON	12.5MG	N74590 004 AUG 30, 1996
AB			25MG	N74590 002 AUG 30, 1996
AB			50MG	N74590 001 AUG 30, 1996
AB			100MG	N74590 003 AUG 30, 1996
AB		ZENITH GOLDLINE	12.5MG	N74590 004 AUG 30, 1996
AB			25MG	N74590 002 AUG 30, 1996
AB			50MG	N74590 001 AUG 30, 1996
AB			100MG	N74590 003 AUG 30, 1996

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION
GEOPEN

	+	ROERIG	EQ 1GM BASE/VIAL	N50306 001
	+		EQ 2GM BASE/VIAL	N50306 004
	+		EQ 5GM BASE/VIAL	N50306 002
	+		EQ 10GM BASE/VIAL	N50306 006
	+		EQ 30GM BASE/VIAL	N50306 007
	@		EQ 1GM BASE/VIAL	N50306 001
	@		EQ 2GM BASE/VIAL	N50306 004
	@		EQ 5GM BASE/VIAL	N50306 002
	@		EQ 10GM BASE/VIAL	N50306 006
	@		EQ 30GM BASE/VIAL	N50306 007

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL
CARBIDOPA AND LEVODOPA

AB		MYLAN	50MG;200MG	N75091 001 SEP 30, 1999

SINEMET CR

	+	DUPONT PHARMS	50MG;200MG	N19856 001 MAY 30, 1991
AB	+	MERCK SHARP DOHME	50MG;200MG	N19856 001 MAY 30, 1991

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OCUPRESS

	+	CIBA	1%	N19972 001 MAY 23, 1990
	+	OTSUKA	1%	N19972 001 MAY 23, 1990

CEFACLOR

CAPSULE; ORAL
CEFACLOR

AB		LEDERLE	EQ 250MG BASE	N64107 001 APR 27, 1995
AB			EQ 500MG BASE	N64107 002 APR 27, 1995
	@		EQ 250MG BASE	N64107 001 APR 27, 1995
	@		EQ 500MG BASE	N64107 002 APR 27, 1995
AB		TEVA	EQ 250MG BASE	N64081 001 SEP 16, 1996
AB			EQ 500MG BASE	N64081 002 SEP 16, 1996
	@		EQ 250MG BASE	N64081 001 SEP 16, 1996
	@		EQ 500MG BASE	N64081 002 SEP 16, 1996

POWDER FOR RECONSTITUTION; ORAL
CEFACLOR

AB		LEDERLE	EQ 125MG BASE/5ML	N64114 001 APR 28, 1995
AB			EQ 187MG BASE/5ML	N64115 001 APR 28, 1995
AB			EQ 250MG BASE/5ML	N64116 001 APR 28, 1995
AB			EQ 375MG BASE/5ML	N64110 001 APR 28, 1995
	@		EQ 125MG BASE/5ML	N64114 001 APR 28, 1995
	@		EQ 187MG BASE/5ML	N64115 001 APR 28, 1995
	@		EQ 250MG BASE/5ML	N64116 001 APR 28, 1995
	@		EQ 375MG BASE/5ML	N64110 001 APR 28, 1995

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

		CEFADROXIL		
AB		BARR	EQ 500MG BASE	N65015 001 JUN 22, 1999

POWDER FOR RECONSTITUTION; ORAL

		CEFADROXIL		
AB		APOTHECON	EQ 125MG BASE/5ML	N62334 001
AB			EQ 250MG BASE/5ML	N62334 002
AB			EQ 500MG BASE/5ML	N62334 003
	@		EQ 125MG BASE/5ML	N62334 001
	@		EQ 250MG BASE/5ML	N62334 002
	@		EQ 500MG BASE/5ML	N62334 003
		DURICEF		
AB	+	BRISTOL MYERS SQUIBB	EQ 125MG BASE/5ML	N50527 002
AB	+		EQ 250MG BASE/5ML	N50527 003
AB	+		EQ 500MG BASE/5ML	N50527 001
	+		EQ 125MG BASE/5ML	N50527 002
	+		EQ 250MG BASE/5ML	N50527 003
	+		EQ 500MG BASE/5ML	N50527 001

TABLET; ORAL

		CEFADROXIL		
AB		RANBAXY	EQ 1GM BASE	N65018 001 APR 23, 1999
		ULTRACEF		
AB		APOTHECON	EQ 1GM BASE	N62390 001 JUN 10, 1982
	@		EQ 1GM BASE	N62390 001 JUN 10, 1982

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

		CEPTAZ		
AP	+	GLAXO WELLCOME	1GM/VIAL	N50646 002 SEP 27, 1990
AP	+		2GM/VIAL	N50646 003 SEP 27, 1990
AP	+		10GM/VIAL	N50646 004 SEP 27, 1990
	+		1GM/VIAL	N50646 002 SEP 27, 1990
	+		2GM/VIAL	N50646 003 SEP 27, 1990

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

		CEPTAZ		
+		GLAXO WELLCOME	10GM/VIAL	N50646 004 SEP 27, 1990
		PENTACEF		
AP		SMITHKLINE BEECHAM	1GM/VIAL	N63322 001 NOV 07, 1995
AP			1GM/VIAL	N64006 001 MAR 31, 1992
AP			2GM/VIAL	N63322 002 NOV 07, 1995
AP			2GM/VIAL	N64006 002 MAR 31, 1992
AP			10GM/VIAL	N64008 002 MAR 31, 1992
			6GM/VIAL	N64008 001 MAR 31, 1992
	@		1GM/VIAL	N63322 001 NOV 07, 1995
	@		1GM/VIAL	N64006 001 MAR 31, 1992
	@		2GM/VIAL	N63322 002 NOV 07, 1995
	@		2GM/VIAL	N64006 002 MAR 31, 1992
	@		6GM/VIAL	N64008 001 MAR 31, 1992
	@		10GM/VIAL	N64008 002 MAR 31, 1992

CEFUROXIME SODIUM

INJECTABLE; INJECTION

		CEFUROXIME		
AB		ASTRA PHARMS	EQ 750MG BASE/VIAL	N64192 002 APR 16, 1998
AP			EQ 1.5GM BASE/VIAL	N64192 001 APR 16, 1998
AP			EQ 7.5GM BASE/VIAL	N64191 001 APR 16, 1998
AB		TEVA	EQ 750MG BASE/VIAL	N64192 002 APR 16, 1998
AP			EQ 1.5GM BASE/VIAL	N64192 001 APR 16, 1998
AP			EQ 7.5GM BASE/VIAL	N64191 001 APR 16, 1998

CEPHALEXIN

CAPSULE; ORAL

	CEPHALEXIN			
AB	RANBAXY	**EQ 250MG BASE**	**N65007 001**	
			SEP 16, 1999	
AB		**EQ 500MG BASE**	**N65007 002**	
			SEP 16, 1999	

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

	CEPHALOTHIN SODIUM			
AP	ABBOTT	**EQ 1GM BASE/VIAL**	**N62547 001**	
			SEP 11, 1985	
AP		**EQ 2GM BASE/VIAL**	**N62547 002**	
			SEP 11, 1985	
	@	EQ 1GM BASE/VIAL	N62547 001	
			SEP 11, 1985	
	@	EQ 2GM BASE/VIAL	N62547 002	
			SEP 11, 1985	

CERIVASTATIN SODIUM

TABLET; ORAL

	BAYCOL			
	+ BAYER	0.3MG	N20740 004	
			JUN 26, 1997	
		0.3MG	N20740 004	
			JUN 26, 1997	
	+	0.4MG	N20740 005	
			MAY 24, 1999	

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

	A-POXIDE			
	@ ABBOTT	5MG	N85517 001	
	@	5MG	N85517 001	
	CHLORDIAZEPOXIDE HCL			
AB	MAST MM	**10MG**	**N86217 001**	
	@	10MG	N86217 001	

CHLOROQUINE PHOSPHATE

TABLET; ORAL

	CHLOROQUINE PHOSPHATE			
AA	MD PHARM	**EQ 150MG BASE**	**N87228 001**	
	@	EQ 150MG BASE	N87228 001	
AA	WEST WARD	**EQ 300MG BASE**	**N83082 002**	
			SEP 17, 1999	

CHLOROTRIANISENE

CAPSULE; ORAL

	CHLOROTRIANISENE			
AA	BANNER PHARMACAPS	**12MG**	**N84652 001**	
	@	12MG	N84652 001	
	TACE			
AA	+ HOECHST MARION RSSL	**12MG**	**N08102 004**	
	+	12MG	N08102 004	

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	CHLORPROMAZINE HCL			
AA	PHARM ASSOC	**100MG/ML**	**N40224 001**	
			JAN 26, 1999	

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE				
AB	ABBOTT	**25MG**	**N87364 001**	> DLT >	
	@	25MG	N87364 001	> ADD >	
AB	DANBURY PHARMA	**25MG**	**N87296 001**	> DLT >	
AB		**25MG**	**N87706 001**	> DLT >	
AB		**50MG**	**N87521 001**	> DLT >	
AB		**50MG**	**N87689 001**	> DLT >	
	@	25MG	N87296 001	> ADD >	
	@	25MG	N87706 001	> ADD >	
	@	50MG	N87521 001	> ADD >	
	@	50MG	N87689 001	> ADD >	
AB	EON	**50MG**	**N87118 001**	> DLT >	
	@	50MG	N87118 001	> ADD >	
AB	KV PHARM	**25MG**	**N87311 001**	> DLT >	
AB		**50MG**	**N87312 001**	> DLT >	
	@	25MG	N87311 001	> ADD >	
	@	50MG	N87312 001	> ADD >	

CHLORTHALIDONE

TABLET; ORAL

		CHLORTHALIDONE		
> DLT >	**AB**	**LEDERLE**	**25MG**	**N87451 001**
> DLT >	**AB**		**50MG**	**N87450 001**
> ADD >		@	25MG	N87451 001
> ADD >		@	50MG	N87450 001

CHOLESTYRAMINE

POWDER; ORAL

		CHOLESTYRAMINE		
	AB	**BAKER NORTON**	**EQ 4GM RESIN/PACKET**	**N74771 001** JUL 09, 1997
	AB		**EQ 4GM RESIN/SCOOPFUL**	**N74771 002** JUL 09, 1997
	AB	ZENITH GOLDLINE	**EQ 4GM RESIN/PACKET**	**N74771 001** JUL 09, 1997
	AB		**EQ 4GM RESIN/SCOOPFUL**	**N74771 002** JUL 09, 1997
		CHOLESTYRAMINE LIGHT		
	AB	COPLEY PHARM	**EQ 4GM RESIN/SCOOPFUL**	**N74555 002** SEP 30, 1998

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

	CATARASE		
+	CIBA	300 UNITS/VIAL	N16938 001
@		300 UNITS/VIAL	N16938 001
	ZOLYSE		
	ALCON	750 UNITS/VIAL	N11903 001
+		750 UNITS/VIAL	N11903 001

CILOSTAZOL

TABLET; ORAL

	PLETAL		
	OTSUKA	50MG	N20863 001 JAN 15, 1999
+		100MG	N20863 002 JAN 15, 1999

CISPLATIN

INJECTABLE; INJECTION

		CISPLATIN		
AP		AM PHARM PARTNERS	**1MG/ML**	**N74735 001** JUL 16, 1999
		PLATINOL-AQ		
AP	+	BRISTOL MYERS	**1MG/ML**	**N18057 004** NOV 08, 1988
	+		1MG/ML	N18057 004 NOV 08, 1988

CLARITHROMYCIN

GRANULE, FOR RECONSTITUTION; ORAL

	BIAXIN		
	ABBOTT	187MG/5ML	N50698 003 SEP 30, 1998

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

		CLEOCIN HCL		
AB	+	PHARMACIA AND UPJOHN	**EQ 75MG BASE**	**N50162 001**
AB			**EQ 75MG BASE**	**N50162 001**
AB	+		**EQ 150MG BASE**	**N50162 002**
AB			**EQ 150MG BASE**	**N50162 002**
			EQ 300MG BASE	N50162 003 APR 14, 1988
	+		EQ 300MG BASE	N50162 003 APR 14, 1988

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

		CLINDAMYCIN PHOSPHATE		
AP		SOLOPAK	**EQ 150MG BASE/ML**	**N62819 001** MAR 15, 1988
AP			**EQ 150MG BASE/ML**	**N62852 001** MAR 17, 1988
	@		EQ 150MG BASE/ML	N62819 001 MAR 15, 1988
	@		EQ 150MG BASE/ML	N62852 001 MAR 17, 1988
AP		STERIS	**EQ 150MG BASE/ML**	**N62900 001** JUN 08, 1988

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	STERIS	EQ 150MG BASE/ML	N63079 001	MAR 05, 1990
	@	EQ 150MG BASE/ML	N62900 001	JUN 08, 1988
	@	EQ 150MG BASE/ML	N63079 001	MAR 05, 1990

SUPPOSITORY; VAGINAL
CLEOCIN

+	PHARMACIA AND UPJOHN	100MG	N50767 001 AUG 13, 1999

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB	ALPHARMA US PHARM	0.05%	N74139 001	AUG 03, 1994
AB	NMC	0.05%	N74139 001	AUG 03, 1994

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	ALTANA	0.05%	N75430 001	MAY 26, 1999
	@	0.05%	N75430 001	MAY 26, 1999

GEL; TOPICAL
CLOBETASOL PROPIONATE

AB	TARO	0.05%	N75279 001	MAY 28, 1999

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE

AT	ALTANA	0.05%	N75391 001	FEB 08, 1999

CLOMIPHENE CITRATE

TABLET; ORAL
CLOMIPHENE CITRATE

AB	PAR PHARM	50MG	N75528 001	AUG 30, 1999

CLOXACILLIN SODIUM

CAPSULE; ORAL
CLOXAPEN

AB	SMITHKLINE BEECHAM	EQ 250MG BASE	N62233 001	
AB		EQ 500MG BASE	N62233 002	
	@	EQ 250MG BASE	N62233 001	
	@	EQ 500MG BASE	N62233 002	

POWDER FOR RECONSTITUTION; ORAL
CLOXACILLIN SODIUM

AA	TEVA	EQ 125MG BASE/5ML	N62268 001	
	+	EQ 125MG BASE/5ML	N62268 001	

TEGOPEN

AA	+ APOTHECON	EQ 125MG BASE/5ML	N61453 001	
	@	EQ 125MG BASE/5ML	N61453 001	

CLOZAPINE

TABLET; ORAL
CLOZAPINE

AB	CREIGHTON	25MG	N74546 001	AUG 30, 1996
AB		100MG	N74546 002	AUG 30, 1996
AB	GENEVA PHARMS	25MG	N74546 001	AUG 30, 1996
AB		100MG	N74546 002	AUG 30, 1996
AB	MYLAN	25MG	N75417 001	MAY 27, 1999
AB		100MG	N75417 002	MAY 27, 1999

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLISTIMETHATE

AP	PHARMA TEK	EQ 150MG BASE/VIAL	N64216 001	FEB 26, 1999

COLY-MYCIN M

AP	+ PARKEDALE	EQ 150MG BASE/VIAL	N50108 002	
	+	EQ 150MG BASE/VIAL	N50108 002	

CORTICOTROPIN

INJECTABLE; INJECTION

CORTICOTROPIN

AP	+ STERIS	**40 UNITS/VIAL**	**N88772 001**	**NOV 21, 1984**
	@	40 UNITS/VIAL	N88772 001	NOV 21, 1984

CROMOLYN SODIUM

CAPSULE; ORAL

GASTROCROM

	+ MEDEVA	100MG	**N19188 001**	**DEC 22, 1989**
	@	100MG	N19188 001	DEC 22, 1989

SOLUTION; INHALATION

CROMOLYN SODIUM

AN	ALPHARMA	**10MG/ML**	**N75067 001**	**JUL 19, 1999**
> ADD > **AN**	MORTON GROVE	**10MG/ML**	**N75346 001**	**OCT 25, 1999**
> ADD > **AN**	ROXANE	**10MG/ML**	**N75175 001**	**SEP 30, 1999**

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

AT	ALCON	**4%**	**N75282 001**	**JUN 16, 1999**

CROMOPTIC

AT	KING PHARMS	**4%**	**N75088 001**	**APR 27, 1999**

CROTAMITON

LOTION; TOPICAL

CROTAN

AT	GALDERMA	**10%**	**N87204 001**
AT	SUMMERS	**10%**	**N87204 001**

CYANOCOBALAMIN

INJECTABLE; INJECTION

RUVITE

AP	SAVAGE LABS	**1MG/ML**	**N80570 002**

CYANOCOBALAMIN

INJECTABLE; INJECTION

RUVITE

	@ SAVAGE LABS	1MG/ML	N80570 002

CYCLOPHOSPHAMIDE

TABLET; ORAL

CYCLOPHOSPHAMIDE

AB	ROXANE	**25MG**	**N40032 001**	**AUG 17, 1999**
AB		**50MG**	**N40032 002**	**AUG 17, 1999**

CYTOXAN

AB	BRISTOL MYERS SQUIBB	**25MG**	**N12141 002**	
AB	+	**50MG**	**N12141 001**	
	+	25MG	N12141 002	
	+	50MG	N12141 001	

CYCLOSPORINE

INJECTABLE; INJECTION

CYCLOSPORINE

> ADD > > ADD > > ADD > **AP**	BEDFORD	**50MG/ML**	**N65004 001**	**OCT 29, 1999**

SANDIMMUNE

> ADD > > ADD > **AP**	+ NOVARTIS	**50MG/ML**	**N50573 001**	**NOV 14, 1983**
> DLT > > DLT >	+	50MG/ML	N50573 001	NOV 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HCL

AA	MD PHARM	**4MG**	**N87566 001**	**NOV 10, 1982**
	@	4MG	N87566 001	NOV 10, 1982

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION
CYSTEINE HCL

@	FRESENIUS KABI	7.25%	N19523 001	
			OCT 22, 1986	
@	PHARMACIA AND UPJOHN	7.25%	N19523 001	
			OCT 22, 1986	

CYTARABINE

INJECTABLE, LIPOSOMAL; INJECTION
DEPOCYT

+	DEPOTECH	10MG/ML	N21041 001	
			APR 01, 1999	
+	SKYEPHARMA	10MG/ML	N21041 001	
			APR 01, 1999	

DACARBAZINE

INJECTABLE; INJECTION
DACARBAZINE

AP	AM PHARM PARTNERS	100MG/VIAL	N75371 001	
			AUG 27, 1999	
AP		200MG/VIAL	N75371 002	
			AUG 27, 1999	

DTIC-DOME

AP	+ BAYER	100MG/VIAL	N17575 001	
	+	100MG/VIAL	N17575 001	

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; INJECTION
SYNERCID

RHONE POULENC RORER	350MG/VIAL; EQ 150MG BASE/VIAL	N50747 001	
		SEP 21, 1999	
	350MG/VIAL; EQ 150MG BASE/VIAL	N50748 001	
		SEP 21, 1999	

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> DLT >
> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
CERUBIDINE

AP	+ BEDFORD	EQ 20MG BASE/VIAL	N64103 001	
			FEB 03, 1995	
	+	EQ 20MG BASE/VIAL	N64103 001	
			FEB 03, 1995	

DAUNORUBICIN HCL

	+ BEDFORD	EQ 5MG BASE/ML	N50731 001	
			JAN 30, 1998	
AP	BIGMAR	EQ 20MG BASE/VIAL	N65000 001	
			MAY 25, 1999	
AP	GENSIA SICOR PHARMS	EQ 20MG BASE/VIAL	N64212 001	
			JUN 23, 1998	

DAUNORUBICIN HCL PRESERVATIVE FREE

AP	+ BEDFORD	EQ 20MG BASE/VIAL	N50731 001	
			JAN 30, 1998	
AP	GENSIA SICOR PHARMS	EQ 20MG BASE/VIAL	N64212 001	
			JUN 23, 1998	

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DDAVP

AB	+ RHONE POULENC RORER	0.01MG/SPRAY	N17922 002	
			FEB 06, 1989	
AB	+	0.01MG/SPRAY	N17922 003	
			AUG 07, 1996	
	@	0.01MG/SPRAY	N17922 002	
			FEB 06, 1989	

DDAVP (NEEDS NO REFRIGERATION)

AB	+ RHONE POULENC RORER	0.01MG/SPRAY	N17922 003	
			AUG 07, 1996	

DESMOPRESSIN ACETATE

AB	BAUSCH AND LOMB	0.01MG/SPRAY	N74830 001	
			JAN 25, 1999	

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
DESOGESTREL AND ETHINYL ESTRADIOL

AB	DURAMED	0.15MG;0.03MG	N75256 001	
			AUG 12, 1999	

ORTHO-CEPT

AB	+ JOHNSON RW	0.15MG;0.03MG	N20301 001	
			DEC 14, 1992	

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
ORTHO-CEPT
+ JOHNSON RW 0.15MG;0.03MG N20301 001 DEC 14, 1992

TABLET, ORAL-28
DESOGESTREL AND ETHINYL ESTRADIOL
AB DURAMED 0.15MG;0.03MG N75256 002 AUG 12, 1999

DESONIDE

CREAM, TOPICAL
TRIDESILON
AB + BAYER 0.05% N17010 001
AB + CLAY PARK 0.05% N17010 001

OINTMENT; TOPICAL
TRIDESILON
AB + BAYER 0.05% N17426 001
AB + CLAY PARK 0.05% N17426 001

DEXAMETHASONE

SUSPENSION/DROPS; OPHTHALMIC
DEXAMETHASONE
AT STERIS 0.1% N89170 001 MAY 09, 1989
@ 0.1% N89170 001 MAY 09, 1989

MAXIDEX
AT + ALCON 0.1% N13422 001
+ 0.1% N13422 001

TABLET; ORAL
DEXONE 0.5
BP SOLVAY 0.5MG N84991 001
0.5MG N84991 001

DEXONE 0.75
BP SOLVAY 0.75MG N84993 001
0.75MG N84993 001

DEXONE 4
BP SOLVAY 4MG N84992 001
4MG N84992 001

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
MAXITROL
AT + ALCON 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N50065 002
AT + FALCON PHARMS 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N50065 002

SUSPENSION/DROPS; OPHTHALMIC
MAXITROL
AT + ALCON 0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N50023 002
AT + FALCON PHARMS 0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N50023 002

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION; OPHTHALMIC
TOBRADEX
> DLT > + ALCON 0.1%;0.3% N50592 001
> DLT > AUG 18, 1988

SUSPENSION/DROPS; OPHTHALMIC
TOBRADEX
> ADD > AB + ALCON 0.1%;0.3% N50592 001
> ADD > AUG 18, 1988
> ADD > TOBRAMYCIN AND DEXAMETHASONE
> ADD > AB BAUSCH AND LOMB 0.1%;0.3% N64134 001
> ADD > OCT 27, 1999

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DECADRON
AP + MERCK EQ 24MG PHOSPHATE/ML N12071 004
+ EQ 24MG PHOSPHATE/ML N12071 004
DEXAMETHASONE SODIUM PHOSPHATE
AP STERIS EQ 4MG PHOSPHATE/ML N83702 001
AP EQ 24MG PHOSPHATE/ML N85606 001
@ EQ 4MG PHOSPHATE/ML N83702 001
@ EQ 24MG PHOSPHATE/ML N85606 001

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

AA	ENDO PHARMS	**5MG**	**N40299 001**	
			MAY 13, 1999	

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 25%

	ABBOTT	250MG/ML	N19445 002	
			NOV 23, 1998	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	**2.5GM/100ML;450MG/100ML**	**N18030 001**	
	@	2.5GM/100ML;450MG/100ML	N18030 001	
	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
	B BRAUN	5GM/100ML;110MG/100ML	N18030 005	
	@	5GM/100ML;110MG/100ML	N18030 005	
	DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
AP	B BRAUN	**5GM/100ML;200MG/100ML**	**N18030 004**	
	@	5GM/100ML;200MG/100ML	N18030 004	
	DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
AP	B BRAUN	**5GM/100ML;330MG/100ML**	**N18030 003**	
	@	5GM/100ML;330MG/100ML	N18030 003	
	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	B BRAUN	**5GM/100ML;450MG/100ML**	**N18030 002**	
	@	5GM/100ML;450MG/100ML	N18030 002	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION
MD-76

AP	MALLINCKRODT	**66%;10%**	**N87073 001**	
		66%;10%	N87073 001	

DIAZEPAM

GEL; RECTAL
DIASTAT

	+ ATHENA	2.5MG/0.5ML	N20648 001	
			JUL 29, 1997	
		5MG/ML	N20648 002	
			JUL 29, 1997	
		10MG/2ML	N20648 003	
			JUL 29, 1997	
		15MG/3ML	N20648 004	
			JUL 29, 1997	
	+	20MG/4ML	N20648 005	
			JUL 29, 1997	
	+ ELAN PHARMS	2.5MG/0.5ML	N20648 001	
			JUL 29, 1997	
		5MG/ML	N20648 002	
			JUL 29, 1997	
		10MG/2ML	N20648 003	
			JUL 29, 1997	
		15MG/3ML	N20648 004	
			JUL 29, 1997	
	+	20MG/4ML	N20648 005	
			JUL 29, 1997	

INJECTABLE; INJECTION
DIAZEPAM

AP	STERIS	**5MG/ML**	**N70911 001**	
			AUG 28, 1986	
AP		**5MG/ML**	**N70930 001**	
			DEC 01, 1986	
	@	5MG/ML	N70911 001	
			AUG 28, 1986	
	@	5MG/ML	N70930 001	
			DEC 01, 1986	

DICLOFENAC POTASSIUM

TABLET; ORAL
DICLOFENAC POTASSIUM

AB	MYLAN	**50MG**	**N75463 001**	
			JUL 26, 1999	

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM

AB	ALCON	0.1%	N20809 001 MAY 04, 1998	> ADD >	
AB	FALCON PHARMS	0.1% †	N20809 001 MAY 04, 1998	> ADD >	

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM

AB	MARTEC	50MG	N74986 001 FEB 26, 1999		
AB		75MG	N74986 002 FEB 26, 1999		
AB	NOVOPHARM	50MG	N74723 001 MAR 30, 1999		
AB	SIDMAK LABS NJ	50MG	N74432 002 JUL 29, 1999		
AB		75MG	N74432 003 JUL 29, 1999		

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL
DICYCLOMINE HCL

AB	MYLAN	10MG	N40319 001 SEP 07, 1999		

TABLET; ORAL
DICYCLOMINE HCL

AB	LANNETT	20MG	N40230 001 FEB 26, 1999		
AB	MYLAN	20MG	N40317 001 SEP 07, 1999		

DIDANOSINE

TABLET, CHEWABLE; ORAL
VIDEX

> DLT >	BRISTOL MYERS SQUIBB	25MG	N20154 002 OCT 09, 1991		
> DLT >	+	150MG	N20154 005 OCT 09, 1991		
> ADD >	+	25MG	N20154 002 OCT 09, 1991		

DIDANOSINE

TABLET, CHEWABLE; ORAL
VIDEX

	BRISTOL MYERS SQUIBB	150MG	N20154 005 OCT 09, 1991		
		200MG	N20154 006 OCT 28, 1999		

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

AB	TARO	0.05%	N75331 001 MAY 14, 1999		

OINTMENT; TOPICAL
DIFLORASONE DIACETATE

AB	ALTANA	0.05%	N75374 001 APR 27, 1999		
AB	TARO	0.05%	N75331 001 MAY 14, 1999		

PSORCON

AB +	PHARMACIA AND UPJOHN	0.05%	N19260 001 AUG 28, 1985		
	+	0.05%	N19260 001 AUG 28, 1985		

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL

AB	PUREPAC PHARM	250MG	N74285 001 MAY 07, 1996		
AB		500MG	N74285 002 MAY 07, 1996		
	@	250MG	N74285 001 MAY 07, 1996		
	@	500MG	N74285 002 MAY 07, 1996		

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM CD

AB3 +	CARDERM	120MG	N20062 001 AUG 10, 1992		

† SEE SECTION 1.3 OF INTRODUCTION

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD				
AB3	+ CARDERM	180MG	N20062 002	DEC 27, 1991
AB3	+	240MG	N20062 003	DEC 27, 1991
AB3	+	300MG	N20062 004	DEC 27, 1991
BC	+	120MG	N20062 001	AUG 10, 1992
BC	+	180MG	N20062 002	DEC 27, 1991
BC	+	240MG	N20062 003	DEC 27, 1991
BC	+	300MG	N20062 004	DEC 27, 1991
CARTIA XT				
AB3	ANDRX PHARMS	120MG	N74752 002	JUL 09, 1998
AB3		180MG	N74752 001	JUL 09, 1998
AB3		240MG	N74752 003	JUL 09, 1998
AB3		300MG	N74752 004	JUL 09, 1998
	@	120MG	N74752 002	JUL 09, 1998
	@	180MG	N74752 001	JUL 09, 1998
	@	240MG	N74752 003	JUL 09, 1998
	@	300MG	N74752 004	JUL 09, 1998
DILTIAZEM HCL				
AB1	BIOVAIL	60MG	N74845 001	SEP 15, 1999
AB1		90MG	N74845 002	SEP 15, 1999
AB1		120MG	N74845 003	SEP 15, 1999

INJECTABLE; INJECTION

DILTIAZEM HCL				
AP	APOTEX	5MG/ML	N75375 001	SEP 30, 1999
AP	MERIDIAN MEDCL TECHN	5MG/ML	N75106 001	APR 29, 1999

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL				
AA	PUREPAC PHARM	25MG	N85156 001	
AA		50MG	N85150 001	
	@	25MG	N85156 001	
	@	50MG	N85150 001	

ELIXIR; ORAL

HYDRAMINE				
AA	ALPHARMA	12.5MG/5ML	N80763 002	
	@	12.5MG/5ML	N80763 002	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DIPIVEFRIN HCL				
AT	ALCON	0.1%	N73636 001	JUN 30, 1994
AT	FALCON PHARMS	0.1%	N73636 001	JUN 30, 1994

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE				
AB	PUREPAC PHARM	25MG	N89425 001	JUL 12, 1990
AB		50MG	N89426 001	JUL 12, 1990
	@	25MG	N89425 001	JUL 12, 1990
	@	50MG	N89426 001	JUL 12, 1990

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC				
+	LILLY	250MG	N50678 001	JUN 19, 1995
+	LILLY RES LABS	250MG	N50678 001	JUN 19, 1995

> ADD > DOFETILIDE

> ADD > CAPSULE; ORAL
> ADD > TIKOSYN
> ADD > PFIZER 0.125MG N20931 001
> ADD > OCT 01, 1999
> ADD > 0.25MG N20931 002
> ADD > OCT 01, 1999
> ADD > + 0.5MG N20931 003
> ADD > OCT 01, 1999

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL
AP SMITH AND NEPHEW 40MG/ML N70046 001
AUG 29, 1985
AP 80MG/ML N70047 001
AUG 29, 1985
@ 40MG/ML N70046 001
AUG 29, 1985
@ 80MG/ML N70047 001
AUG 29, 1985

DOXERCALCIFEROL

CAPSULE; ORAL
HECTOROL
+ BONE CARE 2.5 UGM N20862 001
JUN 09, 1999

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL; INJECTION
DOXIL
+ ALZA 2MG/ML N50718 001
NOV 17, 1995
+ SEQUUS 2MG/ML N50718 001
NOV 17, 1995

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE
@ PUREPAC PHARM EQ 50MG BASE N62479 001
DEC 23, 1983

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE
@ PUREPAC PHARM EQ 100MG BASE N62479 002
DEC 23, 1983
@ RANBAXY EQ 50MG BASE N62479 001
DEC 23, 1983
@ EQ 100MG BASE N62479 002
DEC 23, 1983

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
BENDECTIN
@ HOECHST MARION RSSL 10MG;10MG N10598 002

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL
AP SOLOPAK 2.5MG/ML N71754 001
SEP 06, 1988
AP 2.5MG/ML N71755 001
SEP 06, 1988
@ 2.5MG/ML N71754 001
SEP 06, 1988
@ 2.5MG/ML N71755 001
SEP 06, 1988
AP STERIS 2.5MG/ML N73520 001
NOV 27, 1991
AP 2.5MG/ML N73521 001
NOV 27, 1991
AP 2.5MG/ML N73523 001
NOV 27, 1991
@ 2.5MG/ML N73520 001
NOV 27, 1991
@ 2.5MG/ML N73521 001
NOV 27, 1991
@ 2.5MG/ML N73523 001
NOV 27, 1991

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
LEXXEL
+ ASTRAZENECA 5MG;2.5MG N20668 002 OCT 28, 1998 >ADD<

>ADD< ENTACAPONE

>ADD< TABLET; ORAL
>ADD< COMTAN
>ADD< + ORION 200MG N20796 001 OCT 19, 1999
>ADD<

EPINEPHRINE

INJECTABLE; INJECTION
SUS-PHRINE
+ FOREST LABS 5MG/ML N07942 001
SUS-PHRINE SULFITE-FREE
FOREST LABS 1.5MG/AMP N07942 003 FEB 05, 1999
+ 5MG/ML N07942 001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
ELLENCE
+ PHARMACIA AND UPJOHN 2MG/ML N50778 001 SEP 15, 1999

EPROSARTAN MESYLATE

TABLET; ORAL
TEVETEN
>DLT< SMITHKLINE BEECHAM EQ 300MG BASE N20738 004 DEC 22, 1997
>DLT<
>DLT< EQ 400MG BASE N20738 005 DEC 22, 1997
>DLT<
>DLT< + EQ 600MG BASE N20738 006 MAY 27, 1999
>DLT<
>ADD< UNIMED PHARMS EQ 300MG BASE N20738 004 DEC 22, 1997
>ADD<
>ADD< EQ 400MG BASE N20738 005 DEC 22, 1997
>ADD<

EPROSARTAN MESYLATE

TABLET; ORAL
TEVETEN
+ UNIMED PHARMS EQ 600MG BASE N20738 006 MAY 27, 1999
>ADD<
>ADD<

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION
MEDIHALER ERGOTAMINE
+ 3M 0.36MG/INH N12102 001
@ 0.36MG/INH N12102 001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
ERYC
@ PARKE DAVIS 250MG N62338 001
@ WARNER CHILCOTT 250MG N62338 001

SOLUTION; TOPICAL
C-SOLVE-2
AT BIOGLAN PHAR 2% N62468 001 JUL 03, 1985
AT ZENITH GOLDLINE 2% N62468 001 JUL 03, 1985

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA
BX + BERLEX LABS 0.025MG/24HR N20375 004 MAR 05, 1999

ESCLIM
BX FOURNIER 0.025MG/24HR N20847 001 AUG 04, 1998
BX 0.0375MG/24HR N20847 002 AUG 04, 1998
BX 0.05MG/24HR N20847 003 AUG 04, 1998
BX 0.075MG/24HR N20847 004 AUG 04, 1998
BX 0.1MG/24HR N20847 005 AUG 04, 1998

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESCLIM

BX	WOMEN FIRST HLTHCARE	0.025MG/24HR	N20847 001 AUG 04, 1998	
BX		0.0375MG/24HR	N20847 002 AUG 04, 1998	
BX		0.05MG/24HR	N20847 003 AUG 04, 1998	>ADD>
BX		0.075MG/24HR	N20847 004 AUG 04, 1998	>ADD> >ADD>
BX		0.1MG/24HR	N20847 005 AUG 04, 1998	>ADD> >ADD>

ESTRADIOL

AB	MENOREST	**0.0375MG/24HR**	**N20538 001 JUL 31, 1996**
AB		**0.05MG/24HR**	**N20538 003 JUL 31, 1996**
AB		**0.075MG/24HR**	**N20538 002 JUL 31, 1996**
AB		**0.1MG/24HR**	**N20538 004 JUL 31, 1996**
BX	WYETH AYERST	0.05MG/24HR	N21048 001 SEP 20, 1999
BX		0.075MG/24HR	N21048 002 SEP 20, 1999
BX		0.1MG/24HR	N21048 003 SEP 20, 1999

VIVELLE-DOT

AB	NOVARTIS	**0.0375MG/24HR**	**N20538 001 JUL 31, 1996**
AB		**0.05MG/24HR**	**N20538 003 JUL 31, 1996**
AB		**0.075MG/24HR**	**N20538 002 JUL 31, 1996**
AB		**0.1MG/24HR**	**N20538 004 JUL 31, 1996**

TABLET; ORAL

ESTRADIOL

AB	MYLAN	**0.5MG**	**N40326 001 APR 21, 1999**
AB		**1MG**	**N40326 002 APR 21, 1999**
AB		**2MG**	**N40326 003 APR 21, 1999**

ESTRADIOL

TABLET; VAGINAL

VAGIFEM

+	NOVO NORDISK	25 UGM	N20908 001 MAR 26, 1999

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ORTHO-PREFEST

+	JOHNSON RW	1MG,1MG;0.09MG,N/A	N21040 001 OCT 22, 1999

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

	DURAMED	0.9MG	N20992 003 MAR 24, 1999
		0.625MG	N20992 002 MAR 24, 1999
+		0.9MG	N20992 003 MAR 24, 1999

ESTRONE

INJECTABLE; INJECTION

NATURAL ESTROGENIC SUBSTANCE-ESTRONE

+	STERIS	2MG/ML	N85237 001 NOV 23, 1982
@		2MG/ML	N85237 001 NOV 23, 1982

ESTROPIPATE

CREAM; VAGINAL

OGEN

+	ABBOTT	1.5MG/GM	N84710 001
+	PHARMACIA AND UPJOHN	1.5MG/GM	N84710 001

TABLET; ORAL

ESTROPIPATE

AB	MYLAN	**0.75MG**	**N40359 001 AUG 26, 1999**

ESTROPIPATE

TABLET; ORAL

	ESTROPIPATE			
AB	MYLAN	1.5MG	N40359 002	AUG 26, 1999
AB		3MG	N40359 003	AUG 26, 1999
	OGEN .625			
AB	ABBOTT	0.75MG	N83220 001	
AB	PHARMACIA AND UPJOHN	0.75MG	N83220 001	
	OGEN 1.25			
AB	ABBOTT	1.5MG	N83220 002	
AB	PHARMACIA AND UPJOHN	1.5MG	N83220 002	
	OGEN 2.5			
AB	+ ABBOTT	3MG	N83220 003	
AB	+ PHARMACIA AND UPJOHN	3MG	N83220 003	
	OGEN 5			
AB	ABBOTT	6MG	N83220 004	
AB	PHARMACIA AND UPJOHN	6MG	N83220 004	

ETHCHLORVYNOL

CAPSULE; ORAL

	ETHCHLORVYNOL			
AA	BANNER PHARMACAPS	200MG	N84463 002	
AA		500MG	N84463 003	
AA		750MG	N84463 004	
		100MG	N84463 001	
	@	100MG	N84463 001	
	@	200MG	N84463 002	
	@	500MG	N84463 003	
	@	750MG	N84463 004	
	PLACIDYL			
> DLT > AA	+ ABBOTT	200MG	N10021 007	
> DLT > AA	+	500MG	N10021 002	
> DLT > AA	+	750MG	N10021 010	
> ADD >	+	200MG	N10021 007	
> ADD >	+	500MG	N10021 002	
> ADD >	+	750MG	N10021 010	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	LEVLITE			
	BERLEX LABS	0.02MG;0.1MG	N20860 001	JUL 13, 1998

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	LEVLITE			
+	BERLEX LABS	0.02MG;0.1MG	N20860 001	JUL 13, 1998

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	BREVICON 21-DAY			
AB	SEARLE	0.035MG;0.5MG	N17566 001	
AB	WATSON LABS	0.035MG;0.5MG	N17566 001	
	NORINYL 1+35 21-DAY			
AB	SEARLE	0.035MG;1MG	N17565 001	
AB	WATSON LABS	0.035MG;1MG	N17565 001	
	TRI-NORINYL 21-DAY			
+	SEARLE	0.035MG,0.035MG;0.5MG,1MG	N18977 001	APR 13, 1984
+	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977 001	APR 13, 1984

TABLET; ORAL-28

	BREVICON 28-DAY			
AB	SEARLE	0.035MG;0.5MG	N17743 001	
AB	WATSON LABS	0.035MG;0.5MG	N17743 001	
	NORINYL 1+35 28-DAY			
AB	SEARLE	0.035MG;1MG	N17565 002	
AB	WATSON LABS	0.035MG;1MG	N17565 002	
	TRI-NORINYL 28-DAY			
	SEARLE	0.035MG,0.035MG;0.5MG,1MG	N18977 002	APR 13, 1984
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977 002	APR 13, 1984

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

	FEMHRT			
+	PARKE DAVIS	0.005MG;1MG	N21065 002	OCT 15, 1999

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

	LO/OVRAL			
AB +	WYETH AYERST	0.03MG;0.3MG	N17612 001	

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

	LO/OVRAL			
	+ WYETH AYERST	0.03MG;0.3MG	N17612 001	
	LOW-OGESTREL-21			
AB	SCS	0.03MG;0.3MG	N75288 001 JUL 28, 1999	
AB	WATSON LABS	0.03MG;0.3MG	N75288 001 JUL 28, 1999	

TABLET; ORAL-28

	LO/OVRAL-28			
AB	WYETH AYERST	0.03MG;0.3MG	N17802 001	
		0.03MG;0.3MG	N17802 001	
	LOW-OGESTREL-28			
AB	SCS	0.03MG;0.3MG	N75288 002 JUL 28, 1999	
AB	WATSON LABS	0.03MG;0.3MG	N75288 002 JUL 28, 1999	

ETODOLAC

CAPSULE; ORAL

	ETODOLAC			
AB	NOVOPHARM NC	200MG	N75126 001 SEP 16, 1999	
AB		300MG	N75126 002 SEP 16, 1999	> ADD >

TABLET; ORAL

	ETODOLAC			> ADD >
AB	EON	500MG	N74903 002 APR 19, 1999	> ADD >
AB	NOVOPHARM	400MG	N74847 001 APR 23, 1999	> ADD >
AB		500MG	N74847 002 APR 23, 1999	

ETOPOSIDE

INJECTABLE; INJECTION

	ETOPOSIDE			> DLT >
AP	AM PHARM PARTNERS	20MG/ML	N74983 001 SEP 30, 1998	> DLT >
AP	APPLIED ANAL	20MG/ML	N74983 001 SEP 30, 1998	> ADD >

ETOPOSIDE

INJECTABLE; INJECTION

	ETOPOSIDE			> ADD >
AP	STERIS	20MG/ML	N74228 001 OCT 15, 1996	> ADD >
	@	20MG/ML	N74228 001 OCT 15, 1996	> ADD >
	VEPESID			> ADD >
AP	+ BRISTOL	20MG/ML	N18768 001 NOV 10, 1983	> ADD >
AP	+ BRISTOL MYERS SQUIBB	20MG/ML	N18768 001 NOV 10, 1983	> ADD >

ETRETINATE

CAPSULE; ORAL

	TEGISON		
	ROCHE	10MG	N19369 001 SEP 30, 1986
	+	25MG	N19369 002 SEP 30, 1986
	@	10MG	N19369 001 SEP 30, 1986
	@	25MG	N19369 002 SEP 30, 1986

EXEMESTANE

TABLET; ORAL

	AROMASIN		
+	PHARMACIA AND UPJOHN	25MG	N20753 001 OCT 21, 1999

FENOFIBRATE

CAPSULE; ORAL

	TRICOR (MICRONIZED)		
+	ABBOTT	67MG	N19304 002 FEB 09, 1998
		67MG	N19304 002 FEB 09, 1998
		134MG	N19304 003 JUN 30, 1999
+		200MG	N19304 004 JUN 30, 1999

FERRIC SODIUM GLUCONATE

INJECTABLE; INJECTION
FERRLECIT
+ R AND D LABS — 62.5MG/5ML — N20955 001 FEB 18, 1999

FLUOCINONIDE

OINTMENT; TOPICAL
FLUOCINONIDE
AB TARO — **0.05%** — **N75008 001 JUN 30, 1999**

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL
AP BIGMAR — **50MG/ML** — **N40291 001 MAR 24, 1999**
AP SMITH AND NEPHEW — **50MG/ML** — **N88767 001 DEC 28, 1984**
AP — **50MG/ML** — **N89434 001 MAR 26, 1987**
@ — 50MG/ML — N88767 001 DEC 28, 1984
@ — 50MG/ML — N89434 001 MAR 26, 1987

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
PROZAC
+ LILLY — EQ 20MG BASE — N18936 001 DEC 29, 1987
EQ 20MG BASE — N18936 001 DEC 29, 1987
+ EQ 40MG BASE — N18936 003 JUN 15, 1999
@ EQ 60MG BASE — N18936 004 JUN 15, 1999

TABLET; ORAL
PROZAC
LILLY — EQ 10MG BASE — N20974 001 MAR 09, 1999

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL
PROZAC
+ LILLY — EQ 20MG BASE — N20974 002 MAR 09, 1999
+ EQ 10MG BASE — N20974 001 MAR 09, 1999
@ EQ 20MG BASE — N20974 002 MAR 09, 1999

FOLIC ACID

TABLET; ORAL
FOLIC ACID
AA VINTAGE PHARMS — **1MG** — **N86296 001**
@ 1MG — N86296 001

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE
AP ABBOTT — **10MG/ML** — **N75241 001 MAY 28, 1999**
AP SMITH AND NEPHEW — **10MG/ML** — **N70078 001 FEB 05, 1986**
@ 10MG/ML — N70078 001 FEB 05, 1986
AP STERIS — **10MG/ML** — **N70019 001 SEP 22, 1986**
AP — **10MG/ML** — **N70604 001 JAN 02, 1987**
@ 10MG/ML — N70019 001 SEP 22, 1986
@ 10MG/ML — N70604 001 JAN 02, 1987

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION
FLAXEDIL
+ DAVIS AND GECK — 20MG/ML — N07842 001
+ 100MG/ML — N07842 002
@ 20MG/ML — N07842 001
@ 100MG/ML — N07842 002

GALLIUM NITRATE

INJECTABLE; INJECTION

	GANITE			
+	SOLOPAK	25MG/ML	N19961 002	JAN 17, 1991
@		25MG/ML	N19961 002	JAN 17, 1991

GANIRELIX ACETATE

INJECTABLE; INJECTION

	ANTAGON			
+	ORGANON INC	EQ 250 UGM BASE/0.5ML	N21057 001	JUL 29, 1999

GEMFIBROZIL

TABLET; ORAL

	GEMFIBROZIL			
AB	**PUREPAC PHARM**	**600MG**	**N74360 001**	**AUG 31, 1994**
@		600MG	N74360 001	AUG 31, 1994

GENTAMICIN SULFATE

INJECTABLE; INJECTION

	APOGEN			
AP	**KING PHARMS**	**EQ 10MG BASE/ML**	**N62289 001**	
AP		**EQ 40MG BASE/ML**	**N62289 002**	
@		EQ 10MG BASE/ML	N62289 001	
@		EQ 40MG BASE/ML	N62289 002	
	BRISTAGEN			
AP	**BRISTOL**	**EQ 40MG BASE/ML**	**N62288 001**	
@		EQ 40MG BASE/ML	N62288 001	
	GENTAMICIN SULFATE			
AP	**SOLOPAK**	**EQ 10MG BASE/ML**	**N62507 001**	**JUN 06, 1985**
AP		**EQ 40MG BASE/ML**	**N62507 002**	**JUN 06, 1985**
@		EQ 10MG BASE/ML	N62507 001	JUN 06, 1985
@		EQ 40MG BASE/ML	N62507 002	JUN 06, 1985

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

	GENTAMICIN SULFATE			
AT	**ALCON**	**EQ 0.3% BASE**	**N62196 001**	
AT	FALCON PHARMS	**EQ 0.3% BASE**	N62196 001	

GLIPIZIDE

TABLET; ORAL

	GLUCOTROL			
	PFIZER	2.5MG	N17783 003	MAY 11, 1993
@		2.5MG	N17783 003	MAY 11, 1993

TABLET, EXTENDED RELEASE; ORAL

	GLUCOTROL XL			
+	PFIZER	2.5MG	N20329 003	AUG 10, 1999

GLYBURIDE

TABLET; ORAL

	GLYBURIDE (MICRONIZED)			
AB	MOVA	**4.5MG**	**N74591 003**	DEC 22, 1997
		4.5MG	N74591 003	DEC 22, 1997
AB	MYLAN	**6MG**	**N74792 003**	AUG 17, 1999
AB	NOVOPHARM	**1.5MG**	**N74686 001**	APR 20, 1999
AB		**3MG**	**N74686 002**	APR 20, 1999
AB		**4.5MG**	**N74686 003**	APR 20, 1999
AB		**6MG**	**N74686 004**	APR 20, 1999

GLYCOPYRROLATE

INJECTABLE; INJECTION

	GLYCOPYRROLATE			
AP	**STERIS**	**0.2MG/ML**	**N86947 001**	JUN 24, 1983

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

@	STERIS	0.2MG/ML	N86947 001	
			JUN 24, 1983	

TABLET; ORAL
ROBINUL

+	HORIZON PHARM	1MG	N12827 001	
+	ROBINS AH	1MG	N12827 001	

ROBINUL FORTE

+	HORIZON PHARM	2MG	N12827 002	
+	ROBINS AH	2MG	N12827 002	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	STERIS	**0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML**	**N62788 001**	
			JUN 11, 1987	
	@	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62788 001	
			JUN 11, 1987	

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

> DLT >	AB	SCS	**0.5MG**	**N70720 001**	
> DLT >				**JUN 10, 1986**	
> DLT >	AB		**1MG**	**N70721 001**	
> DLT >				**JUN 10, 1986**	
> DLT >	AB		**2MG**	**N70722 001**	
> DLT >				**JUN 10, 1986**	
> DLT >	AB		**5MG**	**N70723 001**	
> DLT >				**JUN 10, 1986**	
> DLT >	AB		**10MG**	**N70724 001**	
> DLT >				**JUN 10, 1986**	
> DLT >	AB		**20MG**	**N70725 001**	
> DLT >				**SEP 24, 1986**	
> ADD >		@	0.5MG	N70720 001	
> ADD >				JUN 10, 1986	
> ADD >		@	1MG	N70721 001	
> ADD >				JUN 10, 1986	

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

> ADD >	@	SCS	2MG	N70722 001
> ADD >				JUN 10, 1986
> ADD >	@		5MG	N70723 001
> ADD >				JUN 10, 1986
> ADD >	@		10MG	N70724 001
> ADD >				JUN 10, 1986
> ADD >	@		20MG	N70725 001
> ADD >				SEP 24, 1986

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	GENSIA SICOR PHARMS	**EQ 50MG BASE/ML**	**N75393 001**	
			MAY 11, 1999	
AO		**EQ 100MG BASE/ML**	**N75393 002**	
			MAY 11, 1999	

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALOPERIDOL

> DLT >	AA	SCS	**EQ 2MG BASE/ML**	**N70726 001**
> DLT >				**JUN 10, 1986**
> ADD >	@		EQ 2MG BASE/ML	N70726 001
> ADD >				JUN 10, 1986

INJECTABLE; INJECTION
HALOPERIDOL

AP	SOLOPAK	**EQ 5MG BASE/ML**	**N70801 001**	
			DEC 14, 1987	
AP		**EQ 5MG BASE/ML**	**N70864 001**	
			DEC 14, 1987	
	@	EQ 5MG BASE/ML	N70801 001	
			DEC 14, 1987	
	@	EQ 5MG BASE/ML	N70864 001	
			DEC 14, 1987	
AP	STERIS	**EQ 5MG BASE/ML**	**N70713 001**	
			MAY 17, 1988	
AP		**EQ 5MG BASE/ML**	**N70744 001**	
			MAY 17, 1988	
	@	EQ 5MG BASE/ML	N70713 001	
			MAY 17, 1988	

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

@	STERIS	EQ 5MG BASE/ML	N70744 001 MAY 17, 1988

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

AP	**SMITH AND NEPHEW**	**10 UNITS/ML**	**N88458 001** **JUL 26, 1984**
AP		**10 UNITS/ML**	**N88580 001** **OCT 25, 1984**
AP		**100 UNITS/ML**	**N88460 001** **JUL 26, 1984**
AP		**100 UNITS/ML**	**N88581 001** **OCT 25, 1984**
@		10 UNITS/ML	N88458 001 JUL 26, 1984
@		10 UNITS/ML	N88580 001 OCT 25, 1984
@		100 UNITS/ML	N88460 001 JUL 26, 1984
@		100 UNITS/ML	N88581 001 OCT 25, 1984
AP	**SOLOPAK**	**100 UNITS/ML**	**N88459 001** **JUL 26, 1984**
@		100 UNITS/ML	N88459 001 JUL 26, 1984

HEPARIN SODIUM

AP	**SMITH AND NEPHEW**	**1,000 UNITS/ML**	**N88239 001** **JUL 26, 1984**
@		1,000 UNITS/ML	N88239 001 JUL 26, 1984

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	**HALSEY**	**1.5MG/5ML;5MG/5ML**	**N40285 001** **JUL 19, 1999**

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HCL

AP	**+ LUITPOLD**	**20MG/ML**	**N40136 001** **JUN 30, 1997**
+		20MG/ML	N40136 001 JUN 30, 1997
AP	**SOLOPAK**	**20MG/ML**	**N88517 001** **AUG 22, 1985**
@		20MG/ML	N88517 001 AUG 22, 1985

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

AB	**SOLVAY**	**25MG;25MG**	**N87608 001** **FEB 08, 1982**
AB		**50MG;50MG**	**N87213 001** **FEB 08, 1982**
@		25MG;25MG	N87608 001 FEB 08, 1982
@		50MG;50MG	N87213 001 FEB 08, 1982

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

BP	**SOLVAY**	**25MG;15MG;0.1MG**	**N88376 001** **OCT 28, 1983**
@		25MG;15MG;0.1MG	N88376 001 OCT 28, 1983

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

AB	**MAST MM**	**25MG**	**N86192 001**
AB		**50MG**	**N86192 002**
@		25MG	N86192 001
@		50MG	N86192 002

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

	AVALIDE			
	@ SANOFI SYNTHELABO	12.5MG;75MG	N20758 001	
			SEP 30, 1997	
		12.5MG;150MG	N20758 002	
			SEP 30, 1997	
	+	12.5MG;300MG	N20758 003	
			AUG 31, 1998	
	AVAPRO HCT			
	@ SANOFI	12.5MG;75MG	N20758 001	
			SEP 30, 1997	
	+	12.5MG;150MG	N20758 002	
			SEP 30, 1997	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

	TRIAMTERENE AND HYDROCHLOROTHIAZIDE		
AB	DURAMED	25MG;37.5MG	N75052 001
			JUN 18, 1999

HYDROCORTISONE

CREAM; TOPICAL

	HYDROCORTISONE		
AT	G AND W LABS	1%	N84059 001
	@	1%	N84059 001

ENEMA; RECTAL

	CORTENEMA		
AB	+ SOLVAY	100MG/60ML	N16199 001
BR	+	100MG/60ML	N16199 001
	HYDROCORTISONE		
AB	COPLEY PHARM	100MG/60ML	N74171 001
			MAY 27, 1994
BR		100MG/60ML	N74171 001
			MAY 27, 1994

LOTION; TOPICAL

	DERMACORT		
AT	SOLVAY	0.5%	N84573 002
AT		1%	N86462 001
	@	0.5%	N84573 002
	@	1%	N86462 001

HYDROCORTISONE

LOTION; TOPICAL

	HYDROCORTISONE		
AT	THAMES	2.5%	N40247 001
			JUL 23, 1999

SOLUTION; TOPICAL

	TEXACORT		
AT	+ BIOGLAN PHAR	1%	N80425 001
	+	2.5%	N81271 001
			APR 17, 1992
	+ GENDERM	2.5%	N81271 001
			APR 17, 1992
AT	+ MEDICIS	1%	N80425 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL

	HYDROCORTISONE ACETATE		
	+ FERNDALE LABS	2.5%	N40259 001
			JUL 29, 1999

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	HYDROCORTISONE SODIUM SUCCINATE		
AP	STERIS	EQ 100MG BASE/VIAL	N84737 002
AP		EQ 100MG BASE/VIAL	N84738 001
AP		EQ 250MG BASE/VIAL	N84737 001
AP		EQ 500MG BASE/VIAL	N84747 001
AP		EQ 1GM BASE/VIAL	N84748 001
	@	EQ 100MG BASE/VIAL	N84737 002
	@	EQ 100MG BASE/VIAL	N84738 001
	@	EQ 250MG BASE/VIAL	N84737 001
	@	EQ 500MG BASE/VIAL	N84747 001
	@	EQ 1GM BASE/VIAL	N84748 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

	PAREDRINE		
	+ AKORN	1%	N00004 004
	+ PHARMICS	1%	N00004 004

HYDROXYUREA

CAPSULE; ORAL

		HYDROXYUREA		
AB		PAR PHARM	500MG	N75340 001 FEB 24, 1999

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

		HYDROXYZINE HCL		
AP		SOLOPAK	25MG/ML	N87591 001
AP			50MG/ML	N87593 001
AP			50MG/ML	N87595 001
	@		25MG/ML	N87591 001
	@		50MG/ML	N87593 001
	@		50MG/ML	N87595 001

IBUPROFEN

SUSPENSION; ORAL

		MOTRIN		
AB	+	MCNEIL	100MG/5ML	N19842 001 SEP 19, 1989
AB	+	MCNEIL CONS	100MG/5ML	N19842 001 SEP 19, 1989

TABLET; ORAL

		IBUPROFEN		
AB		NORTON HN	400MG	N71145 001 SEP 23, 1986
AB			600MG	N71146 001 SEP 23, 1986
AB			800MG	N71769 001 MAY 08, 1987
AB		ZENITH GOLDLINE	400MG	N71145 001 SEP 23, 1986
AB			600MG	N71146 001 SEP 23, 1986
AB			800MG	N71769 001 MAY 08, 1987
		MOTRIN		
AB		MCNEIL	300MG	N17463 003
AB			400MG	N17463 002
AB			600MG	N17463 004
AB	+		800MG	N17463 005 MAY 22, 1985

IBUPROFEN

TABLET; ORAL

		MOTRIN		
		MCNEIL	100MG	N20418 001 NOV 16, 1994
AB		MCNEIL CONS	300MG	N17463 003
AB			400MG	N17463 002
AB			600MG	N17463 004
AB	+		800MG	N17463 005 MAY 22, 1985
			100MG	N20418 001 NOV 16, 1994

TABLET, CHEWABLE; ORAL

		MOTRIN		
		MCNEIL	50MG	N20135 001 NOV 16, 1994
	+		100MG	N20135 002 NOV 16, 1994
		MCNEIL CONS	50MG	N20135 001 NOV 16, 1994
	+		100MG	N20135 002 NOV 16, 1994

IMIGLUCERASE

INJECTABLE; INJECTION

		CEREZYME		
	+	GENZYME	200 UNITS/VIAL	N20367 001 MAY 23, 1994
			200 UNITS/VIAL	N20367 001 MAY 23, 1994
	+		400 UNITS/VIAL	N20367 002 SEP 22, 1999

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

		INDOCIN SR		
> DLT > AB		EON	75MG	N74464 001 MAY 28, 1998
> DLT >				
> ADD > AB	+		75MG	N74464 001 MAY 28, 1998
> ADD >				
AB	+	MERCK	75MG	N18185 001 FEB 23, 1982

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

	INDOCIN SR			
	@ MERCK	75MG	N18185 001	FEB 23, 1982

INSULIN HUMAN

INJECTABLE; INJECTION

	VELOSULIN BR			
	+ NOVO NORDISK	100 UNITS/ML	N21028 001	JUL 19, 1999

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

> DLT >	RENOVUE-65			
> DLT >	+ BRACCO	65%	N17902 001	
> DLT >	@	65%	N17902 001	
> ADD >				

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

	IPRATROPIUM BROMIDE			
AN	ALPHARMA	0.02%	N75111 001	APR 22, 1999

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

	ISOETHARINE HCL			
AN	INTL MEDICATION	0.08%	N86651 002	
AN		0.1%	N86651 003	
AN	+	0.1%	N86651 003	
AN		0.167%	N86651 005	
AN	+	0.167%	N86651 005	
AN		0.25%	N86651 007	
AN	+	0.25%	N86651 007	
	+	0.08%	N86651 002	
	ISOETHARINE HCL S/F			
AN	+ DEY	0.08%	N89817 001	NOV 22, 1988
AN	+	0.1%	N89818 001	NOV 22, 1988

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

	ISOETHARINE HCL S/F			
AN	+ DEY	0.17%	N89819 001	NOV 22, 1988
AN	+	0.25%	N89820 001	NOV 22, 1988
	@	0.08%	N89817 001	NOV 22, 1988
	@	0.1%	N89818 001	NOV 22, 1988
	@	0.17%	N89819 001	NOV 22, 1988
	@	0.25%	N89820 001	NOV 22, 1988

ISOFLURANE

LIQUID; INHALATION

	FORANE			
AN	+ BAXTER PHARM PROD	99.9%	N17624 001	
AN	+ OHMEDA	99.9%	N17624 001	
	ISOFLURANE			
> ADD > AN	HALOCARBON PRODS	99.9%	N75225 001	OCT 20, 1999
> ADD >				

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

	RIFAMATE			
	+ DOW PHARM	150MG;300MG	N61884 001	
	+ HOECHST MARION RSSL	150MG;300MG	N61884 001	

ISOSORBIDE DINITRATE

TABLET; ORAL

	SORBITRATE			
AB	ZENECA	30MG	N88124 001	AUG 21, 1990
	@	30MG	N88124 001	AUG 21, 1990

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

> ADD >	**AB**	BRIGHTSTONE	**60MG**	**N75166 001**
> ADD >				OCT 07, 1999

ISOTRETINOIN

CAPSULE; ORAL
ACCUTANE

	HLR	10MG	N18662 002
			MAY 07, 1982
		20MG	N18662 004
			MAR 28, 1983
+		40MG	N18662 003
			MAY 07, 1982
	ROCHE	10MG	N18662 002
			MAY 07, 1982
		20MG	N18662 004
			MAR 28, 1983
+		40MG	N18662 003
			MAY 07, 1982

ITRACONAZOLE

INJECTABLE; INJECTION
SPORANOX

+	JANSSEN	10MG/ML	N20966 001
			MAR 30, 1999

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN SULFATE

AP	SOLOPAK	**EQ 75MG BASE/2ML**	**N62605 003**
			FEB 26, 1986
AP		**EQ 500MG BASE/2ML**	**N62605 001**
			FEB 26, 1986
AP		**EQ 1GM BASE/3ML**	**N62605 002**
			FEB 26, 1986
		EQ 75MG BASE/2ML	N62605 003
			FEB 26, 1986
		EQ 500MG BASE/2ML	N62605 001
			FEB 26, 1986

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN SULFATE

@	SOLOPAK	EQ 1GM BASE/3ML	N62605 002
			FEB 26, 1986

KETOCONAZOLE

TABLET; ORAL
KETOCONAZOLE

AB	APPLIED ANAL	**200MG**	**N75341 001**
			JUL 27, 1999
AB	MUTUAL PHARMA	**200MG**	**N75314 001**
			JUN 15, 1999
AB	NOVOPHARM	**200MG**	**N74971 001**
			JUN 15, 1999
AB	SIDMAK LABS CA	**200MG**	**N75362 001**
			JUN 15, 1999
AB	TARO	**200MG**	**N75319 001**
			JUN 15, 1999
AB	TEVA	**200MG**	**N75273 001**
			JUN 15, 1999
	NIZORAL		
AB	+ JANSSEN	**200MG**	**N18533 001**
	+	200MG	N18533 001

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
KETOPROFEN

AB	ANDRX PHARMS	**100MG**	**N75270 002**
			MAR 24, 1999
AB		**150MG**	**N75270 003**
			MAR 24, 1999
AB		**200MG**	**N75270 001**
			MAR 24, 1999
	ORUVAIL		
AB	WYETH AYERST	**100MG**	**N19816 003**
			FEB 08, 1995
AB		**150MG**	**N19816 002**
			FEB 08, 1995
		100MG	N19816 003
			FEB 08, 1995
		150MG	N19816 002
			FEB 08, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

	AP	ABBOTT	**15MG/ML**	**N74993 001** JAN 27, 1999
	AP		**30MG/ML**	**N74993 002** JAN 27, 1999
	AP	BEDFORD	**15MG/ML**	**N75222 001** APR 26, 1999
> ADD >	**AP**		**15MG/ML**	**N75230 002** OCT 25, 1999
> ADD >	**AP**		**30MG/ML**	**N75222 002** APR 26, 1999
	AP		**30MG/ML**	**N75228 001** APR 26, 1999
> ADD >	**AP**		**30MG/ML**	**N75230 001** OCT 25, 1999
> ADD >				

SOLUTION/DROPS; OPHTHALMIC
ACULAR

> ADD >		+ ALLERGAN	0.5%	N19700 001 NOV 09, 1992
> ADD >				
> DLT >		+ SYNTEX	0.5%	N19700 001 NOV 09, 1992
> DLT >				

TABLET; ORAL
KETOROLAC TROMETHAMINE

	AB	SIDMAK LABS CA	**10MG**	**N75284 001** JUN 23, 1999

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC
ZADITOR

		+ CIBA	EQ 0.025% BASE	N21066 001 JUL 02, 1999

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION
LABETALOL HCL

	AP	BEDFORD	**5MG/ML**	**N75303 001** MAY 28, 1999
	AP	FAULDING	**5MG/ML**	**N75242 001** SEP 30, 1999

LABETALOL HYDROCHLORIDE

TABLET; ORAL
LABETALOL HCL

	AB	MUTUAL PHARM	**100MG**	**N75215 001** JUL 29, 1999
	AB		**200MG**	**N75215 002** JUL 29, 1999
	AB		**300MG**	**N75215 003** JUL 29, 1999

TRANDATE

	AB	FARO PHARMS	**100MG**	**N18716 001** MAY 24, 1985
	AB		**200MG**	**N18716 002** AUG 01, 1984
	AB		**300MG**	**N18716 003** AUG 01, 1984
		@	400MG	N18716 004 AUG 01, 1984
	AB	GLAXO WELLCOME	**100MG**	**N18716 001** MAY 24, 1985
	AB		**200MG**	**N18716 002** AUG 01, 1984
	AB		**300MG**	**N18716 003** AUG 01, 1984
		@	400MG	N18716 004 AUG 01, 1984

LACTULOSE

SOLUTION; ORAL
LACTULOSE

	AA	PACO	**10GM/15ML**	**N73160 001** AUG 25, 1992
		@	10GM/15ML	N73160 001 AUG 25, 1992

SOLUTION; ORAL, RECTAL
LACTULOSE

	AA	PACO	**10GM/15ML**	**N72029 001** AUG 25, 1992
		@	10GM/15ML	N72029 001 AUG 25, 1992

LAMIVUDINE

SOLUTION; ORAL

	EPIVIR-HBV				
+	GLAXO WELLCOME	5MG/ML	N20596 002 DEC 08, 1998		
		5MG/ML	N20596 002 DEC 08, 1998		
+		5MG/ML	N21004 001 DEC 08, 1998		

TABLET; ORAL

	EPIVIR-HBV				
+	GLAXO WELLCOME	100MG	N20564 002 DEC 08, 1998		
		100MG	N20564 002 DEC 08, 1998		
+		100MG	N21003 001 DEC 08, 1998		

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

	LEUCOVORIN CALCIUM				
AP	+ ABBOTT	EQ 10MG BASE/ML	N40147 001 JUN 25, 1997		
AP	+ BEDFORD	EQ 200MG BASE/VIAL	N40056 001 MAY 23, 1995		
	LEUCOVORIN CALCIUM PRESERVATIVE FREE				
	+ ABBOTT	EQ 10MG BASE/ML	N40147 001 JUN 25, 1997		
AP	+ BEDFORD	EQ 200MG BASE/VIAL	N40056 001 MAY 23, 1995		
AP	BIGMAR	EQ 10MG BASE/ML	N40286 001 FEB 26, 1999		
AP		EQ 200MG BASE/VIAL	N40258 001 FEB 26, 1999		
	+	EQ 500MG BASE/VIAL	N40286 001 FEB 26, 1999	> DLT >	> DLT >
AP	GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N40332 001 JUN 28, 1999	> ADD >	> ADD >

TABLET; ORAL

	LEUCOVORIN CALCIUM				
AB	INVAMED	EQ 15MG BASE	N75327 001 MAR 24, 1999		
	WELLCOVORIN				
AB	GLAXO WELLCOME	EQ 5MG BASE	N18342 001 JUL 08, 1983		

LEUCOVORIN CALCIUM

TABLET; ORAL

	WELLCOVORIN				
AB	+ GLAXO WELLCOME	EQ 25MG BASE	N18342 002 JUL 08, 1983		
	@	EQ 5MG BASE	N18342 001 JUL 08, 1983		
	@	EQ 25MG BASE	N18342 002 JUL 08, 1983		

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

	XOPENEX				
	+ SEPRACOR	EQ 0.021% BASE	N20837 001 MAR 25, 1999		
	+	EQ 0.042% BASE	N20837 002 MAR 25, 1999		

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CHIROCAINE				
	DARWIN DISCOVERY	EQ 2.5MG BASE/ML	N20997 001 AUG 05, 1999		
		EQ 5MG BASE/ML	N20997 002 AUG 05, 1999		
	+	EQ 7.5MG BASE/ML	N20997 003 AUG 05, 1999		

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

	ORLAAM				
	+ BIODEVELOPMENT	10MG/ML	N20315 001 JUL 09, 1993		
	+ ROXANE	10MG/ML	N20315 001 JUL 09, 1993		

LEVONORGESTREL

TABLET; ORAL

	PLAN B				
	+ WOMENS CAPITAL	0.75MG	N21045 001 JUL 28, 1999		

LIDOCAINE

FILM, EXTENDED RELEASE; TOPICAL
LIDODERM
+ TEIKOKU PHARMA USA 700MG/12HR N20612 001 MAR 19, 1999

FILM, EXTENDED RELEASE; TRANSDERMAL
LIDODERM
+ HIND HLTHCARE 700MG/12HR N20612 001 MAR 19, 1999

LIDOCAINE; PRILOCAINE

AEROSOL; TOPICAL
EMLA
+ ASTRA PHARMS 2.5%;2.5% N20962 001 FEB 04, 1998

DISC; TOPICAL
EMLA
+ ASTRAZENECA 2.5%;2.5% N20962 001 FEB 04, 1998

LISINOPRIL

TABLET; ORAL
ZESTRIL
ZENECA 30MG N19777 006 JAN 20, 1999

LITHIUM CARBONATE

CAPSULE; ORAL
LITHONATE
AB SOLVAY 300MG N16782 001
@ 300MG N16782 001

TABLET; ORAL
LITHIUM CARBONATE
AB PFIZER 300MG N16834 001
AB + 300MG N16834 001
LITHOTABS
AB + SOLVAY 300MG N16980 001
@ 300MG N16980 001

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
IMODIUM
AB + JANSSEN 2MG N17694 001
@ 2MG N17690 001
AB + MCNEIL CONS 2MG N17694 001
@ 2MG N17690 001

LORACARBEF

CAPSULE; ORAL
LORABID
KING PHARMS 200MG N50668 001 DEC 31, 1991
+ 400MG N50668 002 APR 05, 1996
LILLY 200MG N50668 001 DEC 31, 1991
+ 400MG N50668 002 APR 05, 1996

POWDER FOR RECONSTITUTION; ORAL
LORABID
KING PHARMS 100MG/5ML N50667 001 DEC 31, 1991
+ 200MG/5ML N50667 002 DEC 31, 1991
LILLY 100MG/5ML N50667 001 DEC 31, 1991
+ 200MG/5ML N50667 002 DEC 31, 1991

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
LOTEMAX
+ PHARMOS 0.5% N20841 001 MAR 09, 1998
@ 0.5% N20841 001 MAR 09, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19006 001 APR 04, 1984	
@		30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19006 001 APR 04, 1984	

MALATHION

LOTION; TOPICAL

	OVIDE			
@	MEDICIS	0.5%	N18613 001 AUG 02, 1982	
+		0.5%	N18613 001 AUG 02, 1982	

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 25%			
AP	STERIS	12.5GM/50ML	N87460 001 JUN 27, 1983	
@		12.5GM/50ML	N87460 001 JUN 27, 1983	

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

	VERMOX			
AB	+ JANSSEN	100MG	N17481 001	
AB	+ MCNEIL CONS	100MG	N17481 001	

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

	MECLAN			
+	JOHNSON AND JOHNSON	1%	N50518 001	

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

	MECLAN			
@	JOHNSON AND JOHNSON	1%	N50518 001	

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

	CYCRIN			
	ESI	2.5MG	N81239 001 OCT 30, 1992	
		5MG	N81240 001 OCT 30, 1992	
		10MG	N89386 001 SEP 09, 1987	
@		2.5MG	N81239 001 OCT 30, 1992	
@		5MG	N81240 001 OCT 30, 1992	
@		10MG	N89386 001 SEP 09, 1987	

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

	REPRONEX			
BX	FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001 AUG 27, 1999	
BX		150 IU/VIAL;150 IU/VIAL	N21047 002 AUG 27, 1999	

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DEMEROL			
AP	+ ABBOTT	25MG/ML	N05010 007	
AP	+	50MG/ML	N05010 002	
AP	+	75MG/ML	N05010 009	
AP	+	100MG/ML	N05010 003	
AP	+ SANOFI SYNTHELABO	25MG/ML	N05010 007	
AP	+	50MG/ML	N05010 002	
AP	+	75MG/ML	N05010 009	
AP	+	100MG/ML	N05010 003	
	MEPERIDINE HCL			
AP	+ ABBOTT	10MG/ML	N88432 001 AUG 16, 1984	

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

		MEPERIDINE HCL		
AP		ASTRA PHARMS	10MG/ML	N81002 001 JUL 30, 1993
AP		INTL MEDICATION	10MG/ML	N81309 001 AUG 30, 1993
AP		MALLINCKRODT	10MG/ML	N40163 001 MAY 12, 1997
AP		STERIS	10MG/ML	N73443 001 MAR 17, 1992
		MEPERIDINE HCL PRESERVATIVE FREE		
AP	+	ABBOTT	10MG/ML	N88432 001 AUG 16, 1984
AP		ASTRA PHARMS	10MG/ML	N81002 001 JUL 30, 1993
AP		FAULDING	10MG/ML	N40305 001 MAR 10, 1999
AP		INTL MEDICATION	10MG/ML	N81309 001 AUG 30, 1993
AP		MALLINCKRODT	10MG/ML	N40163 001 MAY 12, 1997
AP		STERIS	10MG/ML	N73443 001 MAR 17, 1992

SYRUP; ORAL

		DEMEROL		
AA	+	ABBOTT	50MG/5ML	N05010 005
AA	+	SANOFI SYNTHELABO	50MG/5ML	N05010 005

TABLET; ORAL

		DEMEROL		
AA	+	ABBOTT	50MG	N05010 001
AA	+		100MG	N05010 004
AA	+	SANOFI SYNTHELABO	50MG	N05010 001
AA	+		100MG	N05010 004
		MEPERIDINE HCL		
AA		AMIDE PHARM	50MG	N40331 001 MAY 28, 1999
AA			100MG	N40331 002 MAY 28, 1999
> ADD > AA		DURAMED	50MG	N40318 001 OCT 05, 1999
> ADD > AA			100MG	N40318 002 OCT 05, 1999

MEPROBAMATE

TABLET; ORAL

		MEPROBAMATE		
AA		PHARMAVITE	400MG	N84438 001
	@		400MG	N84438 001

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION

		MERSALYL-THEOPHYLLINE		
	+	STERIS	100MG/ML;50MG/ML	N84875 001
	@		100MG/ML;50MG/ML	N84875 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL

		GLUCOPHAGE		
	+	BRISTOL MYERS SQUIBB	500MG	N20357 001 MAR 03, 1995
			625MG	N20357 003 NOV 05, 1998
			750MG	N20357 004 NOV 05, 1998
			500MG	N20357 001 MAR 03, 1995
	@		625MG	N20357 003 NOV 05, 1998
	@		750MG	N20357 004 NOV 05, 1998

METHOTREXATE SODIUM

INJECTABLE; INJECTION

		METHOTREXATE		
AP		BIGMAR	EQ 25MG BASE/ML	N40263 001 FEB 26, 1999
		METHOTREXATE PRESERVATIVE FREE		
AP		BIGMAR	EQ 25MG BASE/ML	N40265 001 FEB 26, 1999
AP			EQ 1GM BASE/VIAL	N40266 001 FEB 26, 1999
		METHOTREXATE SODIUM		
	+	LEDERLE	EQ 1GM BASE/VIAL	N11719 009 APR 07, 1988

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+ LEDERLE	EQ 1GM BASE/VIAL	N11719 009	APR 07, 1988

TABLET; ORAL
METHOTREXATE SODIUM

AB	DURAMED	EQ 2.5MG BASE	N40233 001	JUN 17, 1999

METHOTRIMEPRAZINE

INJECTABLE; INJECTION
LEVOPROME

	+ IMMUNEX	20MG/ML	N15865 001	
	@	20MG/ML	N15865 001	

METHOXSALEN

INJECTABLE; INJECTION
UVADEX

	+ THERAKOS	0.02MG/ML	N20969 001	FEB 25, 1999

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

AP	SMITH AND NEPHEW	50MG/ML	N70841 001	JAN 02, 1987
	@	50MG/ML	N70841 001	JAN 02, 1987

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
> ADD >
> ADD >
> ADD >

	METADATE ER			
	MEDEVA	10MG	N40306 001	OCT 20, 1999

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

AP	STERIS	EQ 40MG BASE/VIAL	N86953 001	JUL 22, 1982
AP		EQ 125MG BASE/VIAL	N87030 001	JUL 22, 1982
AP		EQ 500MG BASE/VIAL	N88523 001	JUL 24, 1984
AP		EQ 1GM BASE/VIAL	N88524 001	JUL 24, 1984
	@	EQ 40MG BASE/VIAL	N86953 001	JUL 22, 1982
	@	EQ 125MG BASE/VIAL	N87030 001	JUL 22, 1982
	@	EQ 500MG BASE/VIAL	N88523 001	JUL 24, 1984
	@	EQ 1GM BASE/VIAL	N88524 001	JUL 24, 1984

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	SMITH AND NEPHEW	EQ 5MG BASE/ML	N70623 001	MAR 02, 1987
	@	EQ 5MG BASE/ML	N70623 001	MAR 02, 1987

METOLAZONE

TABLET; ORAL
ZAROXOLYN

	MEDEVA	2.5MG	N17386 001
+		2.5MG	N17386 001

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

AB	PUREPAC PHARM	50MG	N74380 001	JUL 29, 1994
AB		100MG	N74380 002	JUL 29, 1994

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

@	PUREPAC PHARM	50MG	N74380 001 JUL 29, 1994
@		100MG	N74380 002 JUL 29, 1994

METRONIDAZOLE

INJECTABLE; INJECTION
FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+ BAXTER HLTHCARE	500MG/100ML	N18657 001
AP	+ SCS	500MG/100ML	N18657 001

METRONIDAZOLE

AP	STERIS	500MG/100ML	N70170 001 APR 01, 1986
@		500MG/100ML	N70170 001 APR 01, 1986

MICONAZOLE NITRATE

INSERT, CREAM; VAGINAL, TOPICAL
MONISTAT DUAL- PAK

+	ADVANCED CARE PRODS	1.2GM,2%	N20968 001 JUN 30, 1999

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

AB	ALPHARMA US PHARM	200MG	N73508 001 NOV 19, 1993
AB	NMC	200MG	N73508 001 NOV 19, 1993

TAMPON; VAGINAL
MONISTAT 5

+	ADVANCED CARE PRODS	100MG	N18592 001 OCT 27, 1989
@		100MG	N18592 001 OCT 27, 1989

MIGLITOL

TABLET; ORAL
GLYSET

	BAYER	25MG	N20682 001 DEC 18, 1996
		50MG	N20682 002 DEC 18, 1996
+		100MG	N20682 003 DEC 18, 1996
	PHARMACIA AND UPJOHN	25MG	N20682 001 DEC 18, 1996
		50MG	N20682 002 DEC 18, 1996
+		100MG	N20682 003 DEC 18, 1996

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL

+	DANBURY PHARMA	EQ 75MG BASE	N63065 002 JUN 10, 1999
AB	GLOBAL PHARM	EQ 50MG BASE	N65005 001 MAR 23, 1999
AB		EQ 100MG BASE	N65005 002 MAR 23, 1999
AB	WARNER CHILCOTT	EQ 50MG BASE	N63066 001 AUG 14, 1990
AB		EQ 100MG BASE	N63067 001 JUL 31, 1990

VECTRIN

AB	WARNER CHILCOTT	EQ 50MG BASE	N63066 001 AUG 14, 1990
AB		EQ 75MG BASE	N63067 002 SEP 15, 1999
AB		EQ 100MG BASE	N63067 001 JUL 31, 1990

NADOLOL

TABLET; ORAL
CORGARD

AB	APOTHECON	20MG	N18063 005 OCT 28, 1986
AB		40MG	N18063 001
AB		80MG	N18063 002

NADOLOL

TABLET; ORAL

		CORGARD		
AB		APOTHECON	120MG	N18063 003
AB	+		160MG	N18063 004
AB		BRISTOL MYERS SQUIBB	20MG	N18063 005
				OCT 28, 1986
AB			40MG	N18063 001
AB			80MG	N18063 002
AB			120MG	N18063 003
AB	+		160MG	N18063 004

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

		NALOXONE HCL		
AP		SMITH AND NEPHEW	0.02MG/ML	N71671 001
				NOV 17, 1987
AP			0.4MG/ML	N71681 001
				NOV 17, 1987
	@		0.02MG/ML	N71671 001
				NOV 17, 1987
	@		0.4MG/ML	N71681 001
				NOV 17, 1987
AP		STERIS	0.4MG/ML	N71339 001
				NOV 18, 1987
	@		0.4MG/ML	N71339 001
				NOV 18, 1987

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

		NALTREXONE HCL		
AB		AMIDE PHARM	50MG	N75274 001
				MAY 26, 1999

NANDROLONE DECANOATE

INJECTABLE; INJECTION

		NANDROLONE DECANOATE		
AO		STERIS	50MG/ML	N88554 001
				FEB 10, 1986
	@		50MG/ML	N88554 001
				FEB 10, 1986

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

		DURABOLIN		
AO	+	ORGANON	25MG/ML	N11891 001
AO	+		50MG/ML	N11891 002
	+		25MG/ML	N11891 001
	+		50MG/ML	N11891 002
		NANDROLONE PHENPROPIONATE		
AO		STERIS	25MG/ML	N86386 001
				JUN 17, 1983
AO			50MG/ML	N87488 001
				JUN 17, 1983
	@		25MG/ML	N86386 001
				JUN 17, 1983
	@		50MG/ML	N87488 001
				JUN 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		NAPHAZOLINE HCL		
AT		AKORN	0.1%	N83590 001
AT		TAYLOR	0.1%	N83590 001

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

		NAPROXEN		
AB		SIDMAK LABS CA	375MG	N75337 001
				MAY 26, 1999
AB			500MG	N75337 002
				MAY 26. 1999

NAPROXEN SODIUM

TABLET; ORAL

		NAPROXEN SODIUM		
AB		PUREPAC PHARM	EQ 250MG BASE	N74319 001
				MAR 20, 1995
AB			EQ 500MG BASE	N74319 002
				MAR 20, 1995
	@		EQ 250MG BASE	N74319 001
				MAR 20, 1995
	@		EQ 500MG BASE	N74319 002
				MAR 20, 1995

NEDOCROMIL SODIUM

SOLUTION; INHALATION
TILADE
+ RHONE POULENC RORER 0.5% N20750 001 OCT 01, 1997
@ 0.5% N20750 001 OCT 01, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL
TPN SUSPENSION
+ INTL MINERALS 15MG/5ML;3.75MG/5ML; 600MG/5ML N08378 003 >DLT >
@ 15MG/5ML;3.75MG/5ML; 600MG/5ML N08378 003 >DLT >
>ADD >
>ADD >

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP
+ ELAN PHARM 11MG/24HR N19983 001 JAN 28, 1992
+ 22MG/24HR N19983 002 JAN 28, 1992
@ 11MG/24HR N19983 001 JAN 28, 1992
@ 22MG/24HR N19983 002 JAN 28, 1992

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN
AP SMITH AND NEPHEW 5MG/ML N70633 001 JUN 19, 1986
@ 5MG/ML N70633 001 JUN 19, 1986

OINTMENT; TRANSDERMAL
NITROGLYCERIN
ALTANA 2% N87355 001 JUL 08, 1988
+ 2% N87355 001 JUL 08, 1988

NITROGLYCERIN

SPRAY, METERED; SUBLINGUAL
NITROLINGUAL PUMPSPRAY
+ POHL BOSKAMP 0.4MG/SPRAY N18705 002 JAN 10, 1997

OLANZAPINE

TABLET; ORAL
ZYPREXA
+ LILLY 2.5MG N20592 001 SEP 30, 1996
2.5MG N20592 001 SEP 30, 1996

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
+ ASTRA PHARMS 10MG N19810 003 OCT 05, 1995
ASTRAZENECA 10MG N19810 003 OCT 05, 1995

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ZOFRAN ODT
GLAXO WELLCOME EQ 4MG BASE N20781 001 JAN 27, 1999
+ EQ 8MG BASE N20781 002 JAN 27, 1999

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL
ZOFRAN
+ GLAXO WELLCOME EQ 8MG BASE N20103 002 DEC 31, 1992
EQ 8MG BASE N20103 002 DEC 31, 1992
+ EQ 24MG BASE N20103 003 AUG 27, 1999

ORLISTAT

CAPSULE; ORAL
XENICAL
+ ROCHE 120MG N20766 001 APR 23, 1999

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
ORPHENADRINE CITRATE
AB KIEL **100MG** **N40249 001** JAN 29, 1999

> ADD > OSELTAMIVIR PHOSPHATE

> ADD > CAPSULE; ORAL
> ADD > TAMIFLU
> ADD > + ROCHE EQ 75MG BASE N21087 001
> ADD > OCT 27, 1999

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE
AA MIKART **5MG/5ML** **N75039 001** JAN 29, 1999

TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL
+ ALZA 15MG N20897 003 JUN 22, 1999

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL
TERRAMYCIN
+ PFIZER EQ 125MG BASE/5ML N60595 001
@ EQ 125MG BASE/5ML N60595 001

OXYTETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
TERRAMYCIN
+ PFIZER EQ 250MG BASE/VIAL N60586 001

OXYTETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
TERRAMYCIN
+ PFIZER EQ 500MG BASE/VIAL N60586 002
@ EQ 250MG BASE/VIAL N60586 001
@ EQ 500MG BASE/VIAL N60586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC
TERRAMYCIN W/ POLYMYXIN
+ PFIZER EQ 5MG BASE/GM; 10,000 UNITS/GM N61841 001
@ EQ 5MG BASE/GM; 10,000 UNITS/GM N61841 001

TABLET; VAGINAL
TERRAMYCIN-POLYMYXIN
+ PFIZER EQ 100MG BASE; 100,000 UNITS N61009 001
@ EQ 100MG BASE; 100,000 UNITS N61009 001

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN
> DLT > **AA** + PARKEDALE **EQ 250MG BASE** **N60521 001**
> DLT > **AA** **EQ 250MG BASE** **N62310 001**
> ADD > **AA** + **EQ 250MG BASE** **N62310 001**
> ADD > @ EQ 250MG BASE N60521 001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL
PAXIL
SMITHKLINE BEECHAM EQ 10MG BASE N20885 001 OCT 09, 1998
EQ 20MG BASE N20885 002 OCT 09, 1998
EQ 30MG BASE N20885 003 OCT 09, 1998
+ EQ 40MG BASE N20885 004 OCT 09, 1998

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL
PAXIL

@	SMITHKLINE BEECHAM	EQ 10MG BASE	N20885 001	OCT 09, 1998
@		EQ 20MG BASE	N20885 002	OCT 09, 1998
@		EQ 30MG BASE	N20885 003	OCT 09, 1998
@		EQ 40MG BASE	N20885 004	OCT 09, 1998

TABLET, EXTENDED RELEASE; ORAL
PAXIL CR

+	SMITHKLINE BEECHAM	EQ 12.5MG BASE	N20936 001	FEB 16, 1999
+		EQ 25MG BASE	N20936 002	FEB 16, 1999

PEMIROLAST POTASSIUM

SOLUTION/DROPS; OPHTHALMIC
ALAMAST

+	SANTEN	0.1%	N21079 001	SEP 24, 1999

PEMOLINE

TABLET; ORAL
CYLERT

AB	ABBOTT	**37.5MG**	**N16832 002**	
AB	+	**75MG**	**N16832 003**	
		18.75MG	N16832 001	
		37.5MG	N16832 002	
	+	75MG	N16832 003	
	+	18.75MG	N16832 001	

PEMOLINE

AB	COPLEY PHARM	**37.5MG**	**N75030 001**	JAN 29, 1999
AB		**75MG**	**N75030 002**	JAN 29, 1999
AB	INVAMED	**37.5MG**	**N75286 002**	JUN 30, 1999
AB		**75MG**	**N75286 003**	JUN 30, 1999

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
TALWIN 50

@	SANOFI SYNTHELABO	EQ 50MG BASE	N16732 001	
@	STERLING WINTHROP	EQ 50MG BASE	N16732 001	

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB	IMPAX PHARM	**400MG**	**N75093 001**	AUG 10, 1999
AB	SIDMAK LABS NJ	**400MG**	**N74874 001**	MAY 25, 1999
AB	TEVA	**400MG**	**N75199 001**	SEP 03, 1999
AB	TORPHARM	**400MG**	**N75191 001**	JUN 09, 1999

PENTOXIL

AB	UPSHER SMITH	**400MG**	**N74962 001**	MAR 31, 1999

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

@	HUESCHEN	2MG	N20184 001 DEC 30, 1993
@		4MG	N20184 002 DEC 30, 1993
@		8MG	N20184 003 DEC 30, 1993
@	SOLVAY	2MG	N20184 001 DEC 30, 1993
@		4MG	N20184 002 DEC 30, 1993
@		8MG	N20184 003 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL
PHENAZINE

AA	MAST MM	**35MG**	**N86523 001**
AA		**35MG**	**N86524 001**

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

	PHENAZINE			
AA	MAST MM	35MG		N86525 001
	@	35MG		N86523 001
	@	35MG		N86524 001
	@	35MG		N86525 001

TABLET; ORAL

	PHENAZINE			
AA	MAST MM	35MG		N87305 001
	@	35MG		N87305 001
	PHENDIMETRAZINE TARTRATE			
AA	MFG CHEMISTS	35MG		N85914 001
	@	35MG		N85914 001
AA	PVT FORM	35MG		N85697 001
	@	35MG		N85697 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	FASTIN			
AA	+ SMITHKLINE BEECHAM	30MG		N17352 001
	@	30MG		N17352 001
	PHENTERMINE HCL			
AA	EON	30MG		N86945 001
				JUL 20, 1983
AA	+	30MG		N86945 001
				JUL 20, 1983

PHENYTOIN SODIUM

INJECTABLE; INJECTION

	PHENYTOIN SODIUM			
AP	STERIS	50MG/ML		N85434 001
	@	50MG/ML		N85434 001

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

	ACTOS			
	TAKEDA	EQ 15MG BASE		N21073 001
				JUL 15, 1999
		EQ 30MG BASE		N21073 002
				JUL 15, 1999

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

	ACTOS			
+	TAKEDA	EQ 45MG BASE		N21073 003
				JUL 15, 1999

POLYETHYLENE GLYCOL 3350

POWDER FOR RECONSTITUTION; ORAL

	MIRALAX			
+	BRAINTREE	17GM/SCOOPFUL		N20698 001
				FEB 18, 1999

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE			
AT	ALCON	10,000 UNITS/ML; EQ 1MG BASE/ML		N64211 001
				APR 13, 1998
AT	FALCON PHARMS	10,000 UNITS/ML; EQ 1MG BASE/ML		N64211 001
				APR 13, 1998

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	MICRO-K			
AB	KV PHARM	8MEQ		N18238 001
AB	ROBINS AH	8MEQ		N18238 001
	MICRO-K 10			
AB	+ KV PHARM	10MEQ		N18238 002
				MAY 14, 1984
AB	+ ROBINS AH	10MEQ		N18238 002
				MAY 14, 1984

GRANULE, FOR RECONSTITUTION ER; ORAL

	MICRO-K LS			
	@ KV PHARM	20MEQ/PACKET		N19561 003
				AUG 26, 1988
	@ ROBINS AH	20MEQ/PACKET		N19561 003
				AUG 26, 1988

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE			
AP	AM PHARM PARTNERS	3MEQ/ML		N80225 003

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

	+	AM PHARM PARTNERS	3MEQ/ML	N80225 003
	+	MILES	4MEQ/ML	N80195 004
	@		4MEQ/ML	N80195 004
AP		STERIS	2MEQ/ML	N86208 001
AP			2MEQ/ML	N89163 001
				MAR 10, 1988
AP			2MEQ/ML	N89421 001
				JAN 02, 1987
AP	+		3MEQ/ML	N86210 001
	@		2MEQ/ML	N86208 001
	@		2MEQ/ML	N89163 001
				MAR 10, 1988
	@		2MEQ/ML	N89421 001
				JAN 02, 1987
	@		3MEQ/ML	N86210 001

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION
THAM-E

	+	ABBOTT	370MG/VIAL;1.75GM/VIAL; 36GM/VIAL	N13025 001
	@		370MG/VIAL;1.75GM/VIAL; 36GM/VIAL	N13025 001

POTASSIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL
POTASSIUM CITRATE

	@	MISSION PHARMA	10MEQ/PACKET	N19647 002
				OCT 13, 1988
	@		20MEQ/PACKET	N19647 001
				OCT 13, 1988
	@	UNIV TX	10MEQ/PACKET	N19647 002
				OCT 13, 1988
	@		20MEQ/PACKET	N19647 001
				OCT 13, 1988

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC
BETADINE

	+	ALCON UNIVERSAL	5%	N18634 001
				DEC 17, 1986
	+	PURDUE FREDERICK	5%	N18634 001
				DEC 17, 1986

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
PRAZOSIN HCL

AB	ZENITH GOLDLINE	EQ 2MG BASE	N71995 001
			MAY 16, 1989
AB		EQ 2MG BASE	N71995 001
			SEP 12, 1988
AB		EQ 5MG BASE	N71745 001
			MAY 16, 1989
AB		EQ 5MG BASE	N71745 001
			SEP 12, 1988

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE

AA	HALSEY	15MG/5ML	N40287 001
			MAY 28, 1999
AA	UDL	15MG/5ML	N40323 001
			MAY 13, 1999

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

	+	STERIS	40MG/ML N83767 001
	@		40MG/ML N83767 001

SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED PLUS

AB	ALCON	1%	N17469 001
AB	FALCON PHARMS	1%	N17469 001

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
HYDELTRASOL

	+ MERCK	EQ 20MG PHOSPHATE/ML	N11583 002	
	@	EQ 20MG PHOSPHATE/ML	N11583 002	

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION
HYDELTRA-TBA

BP	+ MERCK	20MG/ML	N10562 001	
	+	20MG/ML	N10562 001	

PREDNISOLONE TEBUTATE

BP	STERIS	20MG/ML	N83362 001 FEB 17, 1984	
	@	20MG/ML	N83362 001 FEB 17, 1984	

PREDNISONE

TABLET; ORAL
ORASONE

AB	SOLVAY	50MG	N85999 001	
	@	50MG	N85999 001	

PREDNISONE

BX	PHARMAVITE	5MG	N84662 002	
	@	5MG	N84662 002	

PROBENECID

TABLET; ORAL
BENEMID

AB	+ MERCK	500MG	N07898 004	> ADD >
	@	500MG	N07898 004	> ADD >

PROBENECID

AB	MYLAN	500MG	N84211 002	
AB	+	500MG	N84211 002	

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINAMIDE HCL

AP	SMITH AND NEPHEW	100MG/ML	N88530 001 MAR 04, 1985	> DLT > > DLT > > ADD > > ADD >

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINAMIDE HCL

AP	SMITH AND NEPHEW	500MG/ML	N88531 001 MAR 04, 1985	
	@	100MG/ML	N88530 001 MAR 04, 1985	
	@	500MG/ML	N88531 001 MAR 04, 1985	
AP	STERIS	100MG/ML	N87079 001	
AP		500MG/ML	N87080 001	
	@	100MG/ML	N87079 001	
	@	500MG/ML	N87080 001	

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	SMITH AND NEPHEW	EQ 5MG BASE/ML	N89251 001 DEC 04, 1986	
	@	EQ 5MG BASE/ML	N89251 001 DEC 04, 1986	
AP	STERIS	EQ 5MG BASE/ML	N89606 001 JUL 08, 1987	
	@	EQ 5MG BASE/ML	N89606 001 JUL 08, 1987	

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL
COMPAZINE

	SMITHKLINE BEECHAM	EQ 10MG BASE	N21019 001 OCT 06, 1999	
		EQ 15MG BASE	N21019 002 OCT 06, 1999	

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM

	+ SCHERING PLOUGH	100MG	N19781 001 MAY 14, 1998	
		100MG	N19781 001 MAY 14, 1998	

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM

> ADD >	SCHERING PLOUGH	200MG	N19781 002 OCT 15, 1999	
> ADD >				
> ADD >	+	300MG	N19781 003 OCT 15, 1999	
> ADD >				

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMAZINE HCL

AP	STERIS	**50MG/ML**	**N84517 001**	
		25MG/ML	N84510 001	
	@	25MG/ML	N84510 001	
	@	50MG/ML	N84517 001	
	SPARINE			
AP	+ WYETH AYERST	**50MG/ML**	**N10349 006**	
	+	50MG/ML	N10349 006	

PROPOFOL

INJECTABLE; INJECTION
DIPRIVAN

AB	+ ZENECA	**10MG/ML**	**N19627 002 JUN 11, 1996**	
	+	10MG/ML	N19627 002 JUN 11, 1996	
	PROPOFOL			
AB	GENSIA SICOR PHARMS	**10MG/ML**	**N75102 001** JAN 04, 1999	

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
INDERAL LA

AB	+ WYETH AYERST	**60MG**	**N18553 004 MAR 18, 1987**	
AB	+	**80MG**	**N18553 002 APR 19, 1983**	
AB	+	**120MG**	**N18553 003 APR 19, 1983**	
AB	+	**160MG**	**N18553 001 APR 19, 1983**	

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
INDERAL LA

	+ WYETH AYERST	60MG	N18553 004 MAR 18, 1987	
	+	80MG	N18553 002 APR 19, 1983	
	+	120MG	N18553 003 APR 19, 1983	
	+	160MG	N18553 001 APR 19, 1983	
	PROPRANOLOL HCL			
AB	INWOOD LABS	**60MG**	**N72499 001 APR 11, 1989**	
AB		**80MG**	**N72500 001 APR 11, 1989**	
AB		**120MG**	**N72501 001 APR 11, 1989**	
AB		**160MG**	**N72502 001 APR 11, 1989**	
	@	60MG	N72499 001 APR 11, 1989	
	@	80MG	N72500 001 APR 11, 1989	
	@	120MG	N72501 001 APR 11, 1989	
	@	160MG	N72502 001 APR 11, 1989	

INJECTABLE; INJECTION
INDERAL

AP	+ WYETH AYERST	**1MG/ML**	**N16419 001**	
	+	1MG/ML	N16419 001	
	PROPRANOLOL HCL			
AP	SMITH AND NEPHEW	**1MG/ML**	**N70137 001 APR 15, 1986**	
	@	1MG/ML	N70137 001 APR 15, 1986	

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
ACIPHEX

	+ EISAI	20MG	N20973 002 AUG 19, 1999

RANITIDINE BISMUTH CITRATE

TABLET; ORAL
TRITEC
+ GLAXO WELLCOME 400MG N20559 001 AUG 08, 1996
@ 400MG N20559 001 AUG 08, 1996

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL
AB GRANUTEC PHARMS EQ 150MG BASE N74488 001 JUL 31, 1997
AB EQ 300MG BASE N74488 002 JUL 31, 1997
AB NOVOPHARM NC EQ 150MG BASE N74488 001 JUL 31, 1997
AB EQ 300MG BASE N74488 002 JUL 31, 1997
AB PAR PHARM EQ 150MG BASE N75180 001 JAN 28, 1999
AB EQ 300MG BASE N75180 002 JAN 28, 1999

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION
RAPLON
ORGANON 100MG/VIAL N20984 001 AUG 18, 1999
+ 200MG/VIAL N20984 002 AUG 18, 1999

RIFAMPIN

INJECTABLE; INJECTION
RIFADIN
> ADD > AP + HOECHST MARION RSSL 600MG/VIAL N50627 001 MAY 25, 1989
> ADD >
> DLT > + 600MG/VIAL N50627 001 MAY 25, 1989
> DLT >
> ADD > RIFAMPIN
> ADD > AP BEDFORD 600MG/VIAL N64217 001 OCT 29, 1999
> ADD >

RISPERIDONE

TABLET; ORAL
RISPERDAL
JANSSEN 0.25MG N20272 008 MAY 10, 1999
+ 0.5MG N20272 007 JAN 27, 1999

RITONAVIR

CAPSULE; ORAL
NORVIR
ABBOTT 100MG N20945 001 JUN 29, 1999

SOLUTION; ORAL
NORVIR
ABBOTT 80MG/ML N20659 001 MAR 01, 1996
+ 80MG/ML N20659 001 MAR 01, 1996

ROFECOXIB

SUSPENSION; ORAL
VIOXX
MERCK 12.5MG/5ML N21052 001 MAY 20, 1999
+ 25MG/5ML N21052 002 MAY 20, 1999

TABLET; ORAL
VIOXX
MERCK 12.5MG N21042 001 MAY 20, 1999
+ 25MG N21042 002 MAY 20, 1999

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
REQUIP
SMITHKLINE BEECHAM EQ 3MG BASE N20658 006 JAN 27, 1999

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
REQUIP
SMITHKLINE BEECHAM — EQ 4MG BASE — N20658 007 JAN 27, 1999

ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDIA
SMITHKLINE BEECHAM — EQ 2MG BASE — N21071 002 MAY 25, 1999
EQ 4MG BASE — N21071 003 MAY 25, 1999
+ EQ 8MG BASE — N21071 004 MAY 25, 1999

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE
+ HLR — 200MG — N20828 001 NOV 07, 1997
+ ROCHE — 200MG — N20828 001 NOV 07, 1997

SAQUINAVIR MESYLATE

CAPSULE; ORAL
INVIRASE
+ HLR — EQ 200MG BASE — N20628 001 DEC 06, 1995
+ ROCHE — EQ 200MG BASE — N20628 001 DEC 06, 1995

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
ELDEPRYL
@ SOMERSET — 5MG — N19334 001 JUN 05, 1989

SELEGILINE HCL
AB + SOMERSET — 5MG — N19334 001 JUN 05, 1989

SILVER SULFADIAZINE

CREAM; TOPICAL
THERMAZENE
AB KENDALL LP — 1% — N18810 001 DEC 23, 1985
AB SHERWOOD MEDCL — 1% — N18810 001 DEC 23, 1985

SIROLIMUS

SOLUTION; ORAL
RAPAMUNE
+ WYETH AYERST — 1MG/ML — N21083 001 SEP 15, 1999

SODIUM PHENYLBUTYRATE

POWDER; ORAL
BUPHENYL
+ MEDICIS — 3GM/TEASPOONFUL — N20573 001 APR 30, 1996
+ UCYCLYD — 3GM/TEASPOONFUL — N20573 001 APR 30, 1996

TABLET; ORAL
BUPHENYL
+ MEDICIS — 500MG — N20572 001 MAY 13, 1996
+ UCYCLYD — 500MG — N20572 001 MAY 13, 1996

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
GENOTROPIN PRESERVATIVE FREE
+ PHARMACIA AND UPJOHN — 1.5MG/VIAL — N20280 004 AUG 24, 1995 >DLT<
>DLT<
0.2MG/VIAL — N20280 001 JAN 27, 1998 >ADD<
>ADD<
0.4MG/VIAL — N20280 002 JAN 27, 1998 >ADD<
>ADD<
0.6MG/VIAL — N20280 003 JAN 27, 1998 >ADD<
>ADD<
0.8MG/VIAL — N20280 005 JAN 27, 1998 >ADD<

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION

			GENOTROPIN PRESERVATIVE FREE		
> ADD >			PHARMACIA AND UPJOHN	1MG/VIAL	N20280 008 JAN 27, 1998
> ADD >				1.2MG/VIAL	N20280 009 JAN 27, 1998
> ADD >				1.4MG/VIAL	N20280 010 JAN 27, 1998
> ADD >				1.5MG/VIAL	N20280 004 AUG 24, 1995
> ADD >				1.6MG/VIAL	N20280 011 JAN 27, 1998
> ADD >				1.8MG/VIAL	N20280 012 JAN 27, 1998
> ADD >		+		2MG/VIAL	N20280 013 JAN 27, 1998
> ADD >			HUMATROPE		
	BX		LILLY	6MG/VIAL	N19640 005 FEB 04, 1999
		+		12MG/VIAL	N19640 006 FEB 04, 1999
		+		24MG/VIAL	N19640 007 FEB 04, 1999

SOYBEAN OIL

INJECTABLE; INJECTION

			INTRALIPID 10%		
	AP	+	FRESENIUS KABI	10%	N17643 001
	AP	+	PHARMACIA AND UPJOHN	10%	N17643 001
			INTRALIPID 20%		
	AP	+	FRESENIUS KABI	20%	N18449 001
	AP	+		20%	N20248 001 AUG 07, 1996
	AP	+	PHARMACIA AND UPJOHN	20%	N18449 001
	AP	+		20%	N20248 001 AUG 07, 1996
			INTRALIPID 30%		
	AP	+	FRESENIUS KABI	30%	N19942 001 DEC 30, 1993
	AP	+	PHARMACIA AND UPJOHN	30%	N19942 001 DEC 30, 1993

SPIRONOLACTONE

TABLET; ORAL

			ALDACTONE		
	AB		SEARLE	50MG	N12151 008 DEC 30, 1982
	AB	+		100MG	N12151 010 DEC 30, 1983
				50MG	N12151 008 DEC 30, 1982
		+		100MG	N12151 010 DEC 30, 1983
			SPIRONOLACTONE		
	AB		MUTUAL PHARM	50MG	N89424 002 AUG 11, 1999
	AB			100MG	N89424 003 AUG 11, 1999
	AB		PUREPAC PHARM	25MG	N87998 001 OCT 14, 1983
	AB			50MG	N40353 001 JUL 29, 1999
	AB			100MG	N40353 002 JUL 29, 1999
		@		25MG	N87998 001 OCT 14, 1983

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

			SODIUM SULFACETAMIDE		
	AT		AKORN	10%	N83021 001
	AT			15%	N83021 002
	AT			30%	N83021 003
		@		10%	N83021 001
		@		15%	N83021 002
		@		30%	N83021 003
			SULFACETAMIDE SODIUM		
	AT		AKORN	10%	N40215 001 MAY 25, 1999
	AT			30%	N40216 001 MAY 25, 1999

SULFADIAZINE

TABLET; ORAL

			SULFADIAZINE		
	AB	+	EON	500MG	N40091 001 JUL 29, 1994

SULFADIAZINE

TABLET; ORAL
SULFADIAZINE
+ EON 500MG N40091 001
JUL 29, 1994
AB GLOBAL PHARM 500MG N80081 001
@ 500MG N80081 001
AB LANNETT 500MG N80084 001
@ 500MG N80084 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM
AP STERIS 80MG/ML;16MG/ML N71556 001
DEC 29, 1987
@ 80MG/ML;16MG/ML N71556 001
DEC 29, 1987

TACROLIMUS

CAPSULE; ORAL
PROGRAF
+ FUJISAWA HLTHCARE EQ 1MG BASE N50708 001
APR 08, 1994
EQ 0.5MG BASE N50708 003
AUG 24, 1998
EQ 1MG BASE N50708 001
APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
A-N STANNOUS AGGREGATED ALBUMIN
@ NORTH AM CHEMS N/A N17916 001
@ SYNCOR PHARMS N/A N17916 001
PULMOLITE
BS CIS N/A N17776 001
BS DUPONT PHARMS N/A N17776 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION
MICROLITE
CIS N/A N18263 001
MAR 25, 1983
DUPONT PHARMS N/A N18263 001
MAR 25, 1983

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION
NEO TECT KIT
+ DIATIDE N/A N21012 001
AUG 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE
CIS N/A N18467 001
MAR 16, 1982
DUPONT PHARMS N/A N18467 001
MAR 16, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
TECHNESCAN HIDA
DRAXIMAGE N/A N18489 001
OCT 31, 1986
@ N/A N18489 001
OCT 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
OSTEOLITE
AP CIS N/A N17972 001
AP DUPONT PHARMS N/A N17972 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

	INJECTABLE; INJECTION			
	PYROLITE			
	CIS		N/A	N17684 001
	DUPONT PHARMS		N/A	N17684 001

TEMOZOLOMIDE

	CAPSULE; ORAL			
	TEMODAR			
	SCHERING		5MG	N21029 001 AUG 11, 1999
			20MG	N21029 002 AUG 11, 1999
			100MG	N21029 003 AUG 11, 1999
		+	250MG	N21029 004 AUG 11, 1999

TERBUTALINE SULFATE

	INJECTABLE; INJECTION			
	BRETHINE			
AP	NOVARTIS	+	1MG/ML	N18571 001
		+	1MG/ML	N18571 001
	BRICANYL			
AP	HOECHST MARION RSSL	+	1MG/ML	N17466 001
		@	1MG/ML	N17466 001
	TABLET; ORAL			
	BRETHINE			
BP	NOVARTIS		2.5MG	N17849 001
BP		+	5MG	N17849 002
		+	2.5MG	N17849 001
		+	5MG	N17849 002
	BRICANYL			
BP	HOECHST MARION RSSL		2.5MG	N17618 001
BP			5MG	N17618 002
			2.5MG	N17618 001
			5MG	N17618 002

TERIPARATIDE ACETATE

	INJECTABLE; INJECTION			
	PARATHAR			
	RHONE POULENC RORER	+	200 UNITS/VIAL	N19498 001 DEC 23, 1987
		@	200 UNITS/VIAL	N19498 001 DEC 23, 1987

TESTOSTERONE ENANTHATE

	INJECTABLE; INJECTION			
	TESTOSTERONE ENANTHATE			
	STERIS		100MG/ML	N85599 001
		@	100MG/ML	N85599 001

TETRACYCLINE HYDROCHLORIDE

	CAPSULE; ORAL			
	TETRACYCLINE HCL			
AB	PUREPAC PHARM		250MG	N60290 001
AB			500MG	N60290 002
		@	250MG	N60290 001
		@	500MG	N60290 002
	TETRACYN			
AB	PFIPHARMECS		250MG	N60082 003
AB			500MG	N60082 004
		@	250MG	N60082 003
		@	500MG	N60082 004

THEOPHYLLINE

	CAPSULE; ORAL			
	BRONKODYL			
	SANOFI SYNTHELABO	@	100MG	N85264 001
		@	200MG	N85264 002
	STERLING WINTHROP	@	100MG	N85264 001
		@	200MG	N85264 002
	CAPSULE, EXTENDED RELEASE; ORAL			
	THEOCLEAR L.A.-130			
BC	CENT PHARMS	+	130MG	N86569 001 MAY 27, 1982
	SCHWARZ PHARMA	@	130MG	N86569 001 MAY 27, 1982

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEOCLEAR L.A.-260

BC	+ CENT PHARMS	260MG	N86569 002 MAY 27, 1982
	@ SCHWARZ PHARMA	260MG	N86569 002 MAY 27, 1982

INJECTABLE; INJECTION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

	@ B BRAUN	40MG/100ML	N19083 001 NOV 07, 1984
	@ MCGAW	40MG/100ML	N19083 001 NOV 07, 1984

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

	@ B BRAUN	80MG/100ML	N19083 002 NOV 07, 1984
	@ MCGAW	80MG/100ML	N19083 002 NOV 07, 1984

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

	@ B BRAUN	160MG/100ML	N19083 003 NOV 07, 1984
	@ MCGAW	160MG/100ML	N19083 003 NOV 07, 1984

SYRUP; ORAL
AQUAPHYLLIN

AA	FERNDALE LABS	**80MG/15ML**	**N87917 001 JAN 18, 1983**
	@	80MG/15ML	N87917 001 JAN 18, 1983

TABLET, EXTENDED RELEASE; ORAL
SUSTAIRE

BC	ROERIG	100MG	N85665 001
BC		300MG	N85665 002
	@	100MG	N85665 001
	@	300MG	N85665 002

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL

AA	ALPHARMA	**EQ 5MG BASE/ML**	**N70969 001 OCT 16, 1987**
		EQ 5MG BASE/ML	N70969 001 OCT 16, 1987

TIAGABINE HYDROCHLORIDE

TABLET; ORAL
GABITRIL

	+ ABBOTT	2MG	N20646 005 APR 16, 1999

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID

	@ ROCHE	125MG	N19979 001 MAR 24, 1993
AB	+ SYNTEX	**250MG**	**N19979 002** OCT 31, 1991
	@	125MG	N19979 001 MAR 24, 1993
	+ SYNTEX USA	250MG	N19979 002 OCT 31, 1991

TICLOPIDINE HCL

AB	EON	**250MG**	**N75326 001** AUG 20, 1999
AB	GENPHARM	**250MG**	**N75161 001** SEP 13, 1999
AB	INVAMED	**250MG**	**N75318 001** AUG 20, 1999
AB	PUREPAC PHARM	**250MG**	**N75253 001** AUG 20, 1999
AB	TEVA	**250MG**	**N75149 001** AUG 20, 1999
AB	TORPHARM	**250MG**	**N75089 001** JUL 01, 1999

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AB	ALCON	**EQ 0.25% BASE**	**N20963 001** OCT 21, 1998
AB		**EQ 0.5% BASE**	**N20963 002** OCT 21, 1998
AB	FALCON PHARMS	**EQ 0.25% BASE**	**N20963 001** OCT 21, 1998
AB		**EQ 0.5% BASE**	**N20963 002** OCT 21, 1998

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

	TIMOLOL MALEATE				
AT	ADV REMEDIES	EQ 0.5% BASE	N74466 001	> DLT >	
			MAR 25, 1997	> DLT >	
AT	AKORN	EQ 0.5% BASE	N74466 001	> ADD >	
			MAR 25, 1997	> ADD >	
AT	ALCON	EQ 0.25% BASE	N74261 001		
			APR 28, 1995		
AT		EQ 0.5% BASE	N74262 001		
			APR 28, 1995		
	@ FALCON PHARMS	EQ 0.25% BASE	N74261 001		
			APR 28, 1995		
	@	EQ 0.5% BASE	N74262 001		
			APR 28, 1995		

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

	TOBREX				
AT	+ ALCON	0.3%	N50541 001	> ADD >	
AT	+ FALCON PHARMS	0.3%	N50541 001	> DLT >	
				> DLT >	
				> DLT >	
				> DLT >	

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

	TOBRAMYCIN SULFATE		
AP	APOTHECON	EQ 40MG BASE/ML	N64026 001
			MAY 31, 1994
	@	EQ 40MG BASE/ML	N64026 001
			MAY 31, 1994

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

	HYCAMTIN		
	+ SMITHKLINE	EQ 4MG BASE/VIAL	N20671 001
			MAY 28, 1996
	+ SMITHKLINE BEECHAM	EQ 4MG BASE/VIAL	N20671 001
			MAY 28, 1996

TRETINOIN

GEL; TOPICAL

	RETIN-A MICRO		
	+ ADV POLYMER	0.1%	N20475 001
			FEB 07, 1997
	+ JOHNSON AND JOHNSON	0.1%	N20475 001
			FEB 07, 1997

SOLUTION; TOPICAL

	TRETINOIN		
AT	MORTON GROVE	0.05%	N75260 001
			JAN 25, 1999

TRIAMCINOLONE

TABLET; ORAL

	ARISTOCORT			
BP	FUJISAWA HLTHCARE	4MG		N11161 007
BP +		8MG		N11161 011
		1MG		N11161 009
		2MG		N11161 004
BP	LEDERLE	2MG		N11161 004
BP		4MG		N11161 007
BP +		8MG		N11161 011
		1MG		N11161 009
	TRIAMCINOLONE			
BP	ROXANE	2MG		N84708 001
BP		4MG		N84709 001
BP		8MG		N84707 001
	@	2MG		N84708 001
	@	4MG		N84709 001
	@	8MG		N84707 001
BP	TEVA	4MG		N84775 001
	@	4MG		N84775 001

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	ARISTOCORT		
AT	FUJISAWA HLTHCARE	0.025%	N83017 003
AT		0.1%	N83016 004
AT		0.5%	N83015 002
AT	LEDERLE	0.025%	N83017 003
AT		0.1%	N83016 004
AT		0.5%	N83015 002
	ARISTOCORT A		
AT	FUJISAWA HLTHCARE	0.025%	N83017 004

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

ARISTOCORT A

AT		FUJISAWA HLTHCARE	0.025%	N88818 001
				OCT 16, 1984
AT			0.1%	N83016 005
AT			0.1%	N88819 001
				OCT 16, 1984
AT			0.5%	N83015 003
AT			0.5%	N88820 001
				OCT 16, 1984
AT		LEDERLE	0.025%	N83017 004
AT			0.025%	N88818 001
				OCT 16, 1984
AT			0.1%	N83016 005
AT			0.1%	N88819 001
				OCT 16, 1984
AT			0.5%	N83015 003
AT			0.5%	N88820 001
				OCT 16, 1984

GEL; TOPICAL

ARISTOGEL

	@	FUJISAWA HLTHCARE	0.1%	N83380 001
	@	LEDERLE	0.1%	N83380 001

LOTION; TOPICAL

KENALOG

> DLT >	§	APOTHECON	0.025%	N11602 003
> DLT >	§		0.1%	N11602 001
> ADD >	@	BRISTOL MYERS SQUIBB	0.025%	N11602 003
> ADD >	@		0.1%	N11602 001

OINTMENT; TOPICAL

ARISTOCORT

AT		FUJISAWA HLTHCARE	0.1%	N80750 004
AT			0.5%	N80745 002
AT		LEDERLE	0.1%	N80750 004
AT			0.5%	N80745 002

ARISTOCORT A

AT		FUJISAWA HLTHCARE	0.1%	N80750 003
AT			0.1%	N88780 001
				OCT 01, 1984
AT	+		0.5%	N80745 003
	@		0.5%	N88781 001
				OCT 05, 1984
AT		LEDERLE	0.1%	N80750 003

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

ARISTOCORT A

AT		LEDERLE	0.1%	N88780 001
				OCT 01, 1984
AT	+		0.5%	N80745 003
	@		0.5%	N88781 001
				OCT 05, 1984

TRIAMCINOLONE ACETONIDE

AT		ALPHARMA	0.5%	N89913 001
				DEC 23, 1988
	@		0.5%	N89913 001
				DEC 23, 1988

TRIAMCINOLONE DIACETATE

SYRUP; ORAL

ARISTOCORT

	FUJISAWA HLTHCARE	2MG/5ML	N11960 004
	LEDERLE	2MG/5ML	N11960 004

TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLORMAS

BP		MAST MM	4MG	N86259 001
	@		4MG	N86259 001

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHEXYPHENIDYL HCL

AA		MIKART	2MG/5ML	N40251 001
				SEP 27, 1999

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HCL

AP		SMITH AND NEPHEW	100MG/ML	N88960 001
				APR 04, 1986
	@		100MG/ML	N88960 001
				APR 04, 1986

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL

		SULFA-TRIPLE #2			
AB	+	GLOBAL PHARM	167MG;167MG;167MG	N80079 001	
	@		167MG;167MG;167MG	N80079 001	
		TRIPLE SULFOID			
AB		PAL PAK	167MG;167MG;167MG	N80094 001	
	+		167MG;167MG;167MG	N80094 001	

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	TROPICAMIDE			
AT	STERIS	0.5%	N89171 001	
			DEC 28, 1990	
	@	0.5%	N89171 001	
			DEC 28, 1990	

UREA, C-13

POWDER FOR RECONSTITUTION; ORAL

	PYLORI-CHEK BREATH TEST			
	+ ALIMENTERICS	100MG/VIAL	N20900 001	
			FEB 04, 1999	

VALRUBICIN

SOLUTION;

	VALSTAR PRESERVATIVE FREE			
	+ ANTHRA	40MG/ML	N20892 001	
			SEP 25, 1998	

SOLUTION; INTRAVESICAL

	VALSTAR PRESERVATIVE FREE			
	+ ANTHRA	40MG/ML	N20892 001	
			SEP 25, 1998	

VECURONIUM BROMIDE

INJECTABLE; INJECTION

		VECURONIUM BROMIDE			
> ADD >	AP	ABBOTT	10MG/VIAL	N75164 001	
> ADD >				OCT 21, 1999	

VECURONIUM BROMIDE

INJECTABLE; INJECTION

		VECURONIUM BROMIDE			
> ADD >	AP	ABBOTT	20MG/VIAL	N75164 002	
> ADD				OCT 21, 1999	
	AP	ESI LEDERLE	10MG/VIAL	N75218 001	
				AUG 23, 1999	
	AP		20MG/VIAL	N75218 002	
				AUG 23, 1999	
	AP	GENSIA	10MG/VIAL	N74688 001	
				AUG 25, 1999	
	AP		20MG/VIAL	N74688 002	
				AUG 25, 1999	

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		VERAPAMIL HCL			
	AB	MYLAN	120MG	N75138 001	
				APR 20, 1999	
	AB		180MG	N75138 002	
				APR 20, 1999	
	AB		240MG	N75138 003	
				APR 20, 1999	
		VERELAN			
	+	ELAN	120MG	N19614 001	
				MAY 29, 1990	
	+		180MG	N19614 003	
				JAN 09, 1992	
	+		240MG	N19614 002	
				MAY 29, 1990	
	AB	+ ELAN PHARM	120MG	N19614 001	
				MAY 29, 1990	
	AB	+	180MG	N19614 003	
				JAN 09, 1992	
	AB	+	240MG	N19614 002	
				MAY 29, 1990	

INJECTABLE; INJECTION

		VERAPAMIL HCL			
	AP	SMITH AND NEPHEW	2.5MG/ML	N70696 001	
				JUL 31, 1987	
		@	2.5MG/ML	N70696 001	
				JUL 31, 1987	

TABLET, EXTENDED RELEASE; ORAL

		VERAPAMIL HCL			
	AB	DURAMED	120MG	N75072 001	
				MAY 25, 1999	

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	VERAPAMIL HCL			
AB	DURAMED	240MG	N75072 003	MAY 25, 1999

VINCRISTINE SULFATE

INJECTABLE; INJECTION

	VINCRISTINE SULFATE PFS			
AP	GENSIA SICOR PHARMS	1MG/ML	N75493 001	SEP 01, 1999

VITAMIN A PALMITATE

CAPSULE; ORAL

	DEL-VI-A			
AA	DEL RAY LABS	EQ 50,000 UNITS BASE	N80830 001	
	@	EQ 50,000 UNITS BASE	N80830 001	

WARFARIN SODIUM

TABLET; ORAL

	COUMADIN			
AB	+ DUPONT MERCK	2MG	N09218 013	
AB		2MG	N09218 013	
AB		2.5MG	N09218 018	
AB	+	2.5MG	N09218 018	
AB		5MG	N09218 007	
AB	+	5MG	N09218 007	
	WARFARIN SODIUM			
AB	TARO	1MG	N40301 002	JUL 15, 1999
AB		2MG	N40301 003	JUL 15, 1999
AB		2.5MG	N40301 004	JUL 15, 1999
AB		3MG	N40301 005	JUL 15, 1999
AB		4MG	N40301 006	JUL 15, 1999
AB		5MG	N40301 007	JUL 15, 1999
AB		6MG	N40301 008	JUL 15, 1999

WARFARIN SODIUM

TABLET; ORAL

	WARFARIN SODIUM			
AB	TARO	7.5MG	N40301 009	JUL 15, 1999
AB		10MG	N40301 001	JUL 15, 1999

XYLOSE

POWDER; ORAL

	XYLO-PFAN			
AA	+ SAVAGE LABS	25GM/BOT	N17605 001	
	@	25GM/BOT	N17605 001	
	XYLOSE			
AA	LYNE	25GM/BOT	N18856 001	MAR 26, 1987
	+	25GM/BOT	N18856 001	MAR 26, 1987

ZALEPLON

CAPSULE; ORAL

	SONATA			
	WYETH AYERST	5MG	N20859 001	AUG 13, 1999
	+	10MG	N20859 002	AUG 13, 1999

ZANAMIVIR

CAPSULE; INHALATION

	RELENZA			
	+ GLAXO WELLCOME	5MG	N21036 001	JUL 26, 1999

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN			
+ G AND W LABS	120MG		N18060 001
+	325MG		N18060 003
			DEC 18, 1986
+	650MG		N18060 002
	120MG		N18060 001
	325MG		N18060 003
			DEC 18, 1986
	650MG		N18060 002
ACETAMINOPHEN			
ASCENT PEDS	120MG		N18337 003
			SEP 12, 1983
	325MG		N18337 002
+	650MG		N18337 001
UPSHER SMITH	120MG		N18337 003
			SEP 12, 1983
	325MG		N18337 002
	650MG		N18337 001
INFANTS' FEVERALL			
ASCENT PEDS	80MG		N18337 004
			AUG 26, 1992
UPSHER SMITH	80MG		N18337 004
			AUG 26, 1992

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONTAC			
+ SMITHKLINE	8MG;75MG		N18099 001
@	8MG;75MG		N18099 001
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE			
CENT PHARMS	8MG;75MG		N18809 001
			MAY 07, 1984
+	8MG;75MG		N18809 001
			MAY 07, 1984

TABLET, EXTENDED RELEASE; ORAL

CONTAC			
NOVARTIS	12MG;75MG		N19613 001
			JUN 13, 1986
+	12MG;75MG		N19613 001
			JUN 13, 1986
TRIAMINIC-12			
+ NOVARTIS	12MG;75MG		N18115 001
@	12MG;75MG		N18115 001

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200			
+ SMITHKLINE BEECHAM	200MG/20ML		N20951 001
			JUL 09, 1999

TABLET; ORAL

CIMETIDINE			
DANBURY PHARMA	200MG		N75425 001
			JUL 29, 1999
ZENITH GOLDLINE	200MG		N75345 001
			JUN 16, 1999

CLOTRIMAZOLE

CREAM; TOPICAL

LOTRIMIN AF			
SCHERING PLOUGH	1%		N17619 002
			OCT 27, 1989

LOTION; TOPICAL

LOTRIMIN AF			
SCHERING	1%		N18813 002
			OCT 27, 1989

SOLUTION; TOPICAL

LOTRIMIN AF			
SCHERING PLOUGH	1%		N17613 002
			OCT 27, 1989

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

MEDIHALER-EPI			
+ 3M	0.3MG/INH		N10374 003
@	0.3MG/INH		N10374 003

FAMOTIDINE

TABLET; ORAL

PEPCID AC			
MERCK	10MG		N20902 001
			AUG 05, 1999

IBUPROFEN

SUSPENSION; ORAL
IBUPROFEN
ALPHARMA 100MG/5ML N74916 001 APR 30, 1999

TABLET; ORAL
IBUPROFEN
LNK 200MG N75010 001 MAR 01, 1999
200MG N75139 001 MAR 01, 1999
NORTON HN 200MG N71144 001 JAN 20, 1987
200MG N72901 001 DEC 19, 1991
200MG N72903 001 DEC 19, 1991
ZENITH GOLDLINE 200MG N71144 001 JAN 20, 1987
200MG N72901 001 DEC 19, 1991
200MG N72903 001 DEC 19, 1991

JUNIOR STRENGTH IBUPROFEN
PERRIGO 100MG N75367 001 APR 22, 1999

IBUPROFEN POTASSIUM

CAPSULE; ORAL
PROVEL
+ NOVARTIS 200MG N20402 001 APR 20, 1995
+ WHITEHALL ROBINS 200MG N20402 001 APR 20, 1995

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION
LENTE ILETIN II
+ LILLY 100 UNITS/ML N18477 001
@ 100 UNITS/ML N18477 001

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
M-ZOLE 3 COMBINATION PACK
ALPHARMA US PHARM 2%,200MG N74926 001 APR 16, 1999

MICONAZOLE NITRATE COMBINATION PACK
PERRIGO 2%,200MG N75329 001 APR 20, 1999

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE
ALPHARMA US PHARM 100MG N73507 001 NOV 19, 1993
NMC 100MG N73507 001 NOV 19, 1993

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)
PERRIGO 2% N75357 001 JUL 30, 1999

MINOXIDIL (FOR WOMEN)
PERRIGO 2% N75357 002 JUL 30, 1999

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM
GRANUTEC EQ 200MG BASE N74635 001 JAN 13, 1997
NOVOPHARM NC EQ 200MG BASE N74635 001 JAN 13, 1997

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP
+ ELAN PHARM 11MG/24HR N19983 003 DEC 23, 1998
+ 22MG/24HR N19983 004 DEC 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX		
WATSON LAB	EQ 2MG BASE	N74507 001 MAR 15, 1999
	EQ 4MG BASE	N74707 001 MAR 19, 1999

NONOXYNOL-9

SPONGE; VAGINAL

TODAY		
@ ALLENDALE PHARMS	1GM	N18683 001 APR 01, 1983
@ WHITEHALL ROBINS	1GM	N18683 001 APR 01, 1983

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HCL		
PERRIGO	120MG	N75153 001 FEB 26, 1999

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HCL		
NOVOPHARM	EQ 75MG BASE	N75094 001 JUN 21, 1999
RANBAXY	EQ 75MG BASE	N75132 001
ZANTAC 75		
+ GLAXO WELLCOME	EQ 75MG BASE	N20520 001 DEC 19, 1995
+ WARNER LAMBERT	EQ 75MG BASE	N20520 001 DEC 19, 1995

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL		
+ NOVARTIS	1%	N20980 001 MAR 09, 1999

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 10 OCT '99

NO OCTOBER 1999 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
111Indium pentetreotide TN= SomatoTher	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation 1600 Canal St. 10th Floor New Orleans, LA 70112 DD=06/10/1999
166Ho-DOTMP TN=	Treatment of multiple myeloma.	NeoRx Corporation 410 W. Harrison Seattle, WA 98119 DD=02/10/1999
506U78 TN=	Treatment of chronic lymphocytic leukemia.	Glaxo Wellcome, Inc. Five Moore Dr. P.O. Box 13398 Durham, NC 27709 DD=09/02/1999
6-hydroxymethylacylfulvene TN=	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=04/06/1999
6-hydroxymethylacylfulvene TN=	Treatment of ovarian cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=07/06/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
6-hydroxymethylacylfulvene TN=	Treatment of renal cell carcinoma.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=07/27/1999
Alitretinoin TN= Panretin	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998
Amifostine TN= Ethyol	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998 MA=06/24/1999
Amifostine TN= Ethyol	Treatment of myelodysplastic syndromes.	US Bioscience, Inc. One Tower Bridge 100 Front St., Suite 400 West Conshohocken, PA 19428 DD=10/04/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized TN= Humate-P	Treatment and prevention of bleeding in hemophilia A (classical hemophilia) in adult patients; and treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate in adult and pediatric patients.	Centeon Pharma GmbH Emil-von-Behring-Strasse 76 35041 Marburg Germany, DD=10/16/1992 MA=04/01/1999
Artesunate TN=	Treatment of malaria.	World Health Organisation Special Programme for Research and Training in Tropical Diseases Via Appia Geneva 27, Switzerland DD=07/19/1999
Atovaquone TN= Mepron	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development 5 Moore Drive PO Box 13398 Research Triangle Park, NC 27709 DD=08/14/1991 MA=01/05/1999
Autologous DNP-conjugated tumor vaccine TN= M-Vax	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc. 4520 Main St. Suite 930 Kansas City, MO 64111 DD=02/23/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Azathioprine TN= Imuran	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc. 787 Seventh Ave., 48th Floor New York, NY 10019 DD=09/14/1999
Beraprost TN=	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	United Therapeutics Corporation 68 T.W. Alexander Drive, PO Box 14186 Research Triangle Park, NC 27709 DD=04/29/1999
Bexarotene TN= Targretin	Treatment of cutaneous T-cell lymphoma.	Ligand Pharmaceuticals, Inc. 10275 Science Center Dr. San Diego, CA 92121 DD=06/18/1999
Bleomycin TN= Blenoxane	Treatment of pancreatic cancer.	Genetronics, Inc. 11199 Sorrento Valley Rd. San Diego, CA 92121 DD=02/09/1999
Botulinum toxin type A TN= Dysport	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited 1 Bath Rd., Maidenhead Berkshire SL6 4UH England, UK DD=10/20/1999
Busulfan TN= Busulfex	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=07/28/1994 MA=02/04/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
CT-2584 mesylate TN=	Treatment of adult soft tissue sarcoma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Suite 400 Seattle, WA 98119 DD=04/16/1999
CT-2584 mesylate TN=	Treatment of malignant mesothelioma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Seattle, WA 98119 DD=04/16/1999
Caffeine TN= Cafcit	Treatment of apnea of prematurity.	O.P.R. Development, L.P. 1501 Wakarusa Drive Lawrence, KS 66047 DD=09/20/1988 MA=09/21/1999
Coagulation factor VIIa (recombinant) TN= NovoSeven	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk Pharmaceuticals, Inc. 100 Overlook Center Suite 200 Princeton, NJ 08540 DD=06/06/1988 MA=03/25/1999
Cytarabine liposomal TN= DepoCyt	Treatment of neoplastic meningitis.	DepoTech Corporation 10450 Science Center Drive San Diego, CA 92121 DD=06/02/1993 MA=04/01/1999
Decitabine TN=	Treatment of myelodysplastic syndromes.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem, The Netherlands DD=03/08/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Decitabine TN=	Treatment of chronic myelogenous leukemia.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem, The Netherlands DD=03/08/1999
Denileukin diftitox TN= Ontak	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	Seragen, Inc. 97 South Street Hopkinton, MA 01748 DD=08/21/1996 MA=02/05/1999
Doxorubicin liposome TN= Doxil	Treatment of ovarian cancer.	Alza Corporation 1550 Plymouth St. PO Box 7210 Mountain View, CA 94039 DD=11/04/1998 MA=06/28/1999
Epirubicin TN= Ellence	Treatment of breast cancer.	Pharmacia & Upjohn Company 0634-298-113 7000 Portage Rd. Kalamazoo, MI 49001 DD=09/14/1999 MA=09/15/1999
Epoprostenol TN= Flolan	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	Glaxo Wellcome Inc. Five Moore Dr. PO Box 13398 Research Triangle Park, NC 27709 DD=03/22/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Etanercept TN= Enbrel	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=10/27/1998 MA=05/27/1999
Etanercept TN= Enbrel	Treatment of Wegener's granulomatosis.	Immunex Corporation 51 University Street Seattle, WA 98101 DD=04/06/1999
Exemestane TN= Aromasin	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn 7000 Portage Road Mail Stop: 0636-298-113 Kalamazoo, MI 49001 DD=09/19/1991 MA=10/21/1999
Fluoxetine TN= Prozac	Treatment of autism.	Hollander, MD, Eric Mt. Sinai School of Medicine, Dept. of Psychiatry Box 1230, One Gustave L. Levy Place New York, NY 10029 DD=04/30/1999
Guanfacine TN= Tenex	Treatment of fragile X syndrome.	Watson Laboratories, Inc. 311 Bonnie Circle PO Box 1900 Corona, CA 91718 DD=08/05/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex TN= Allovectin-7	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated 9373 Towne Centre Dr., Suite 100 San Diego, CA 92121 DD=09/30/1999
Humanized MAb (IDEC-131) to CD40L TN=	Treatment of systemic lupus erythematosus.	Idec Pharmaceuticals Corporation 3030 Callan Rd. San Diego, CA 92121 DD=02/09/1999
Interferon beta-1a (recombinant human) TN= Avonex	Treatment of pulmonary fibrosis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=01/07/1999
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B) TN= 131IchTNT-1	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Techniclone Corporation 14282 Franklin Ave. Tustin, CA 92780 DD=02/12/1999
Japanese encephalitis vaccine (live, attenuated) TN=	Prevention of Japanese encephalitis.	Boran Pharmaceuticals 3F, Koryo Academytel, 437-3 Ahyun-Dong, Mapo-Gu, Seoul 121-010 South Korea, DD=05/19/1999
L-5-hydroxytryptophan TN=	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc. 311 Bonnie Circle P.O. Box 1900 Corona, CA 91718 DD=01/20/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
L-glutamyl-L-tryptophan TN=	Treatment of AIDS-related Kaposi's sarcoma.	Cytran Incorporated 10230 N.E. Points Dr. Suite 530 Kirkland, WA 98033 DD=10/20/1999
Lactic acid TN= Aphthaid	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc. SUNY Farmingdale Conklin Hall Farmingdale, NY 11735 DD=06/29/1999
Lidocaine patch 5% TN= Lidoderm Patch	For relief of allodynia (painful hypersensitivity), and chronic pain in post-herpetic neuralgia.	Hind Health Care, Inc. 3707 Williams Rd., Suite 101 San Jose, CA 95117 DD=10/24/1995 MA=03/19/1999
Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II) TN=	Treatment of malignant mesothelioma.	Aronex Pharmaceuticals, Inc. 8707 Technolgoy Forest Place The Woodlands, TX 77381 DD=09/01/1999
Lisofylline TN=	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc. 201 Elliot Ave. W., Suite 400 Seattle, WA 98119 DD=06/10/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Marijuana TN=	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc. 3 Francis St. Belmont, MA 02478 DD=05/25/1999
Mitoxantrone TN= Novantrone	Treatment of secondary-progressive multiple sclerosis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=08/13/1999
Mitoxantrone TN= Novantrone	Treatment of progressive-relapsing multiple sclerosis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=08/13/1999
Murine MAb to polymorphic epithelial mucin, human milk fat globule 1 TN= Theragyn	Adjuvant treatment of ovarian cancer.	Antisoma West Africa House Hanger Lane London W5 3QR, UK DD=03/22/1999
N-acetylgalactosamine-4-sulfatase, recombinant human TN=	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc. 11 Pimental Court Novato, CA 94949 DD=02/17/1999
Parovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine TN= MEDI-491	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg, MD 20878 DD=05/07/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Peginterferon alfa-2a TN= PEGASYS	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley, NJ 07110 DD=09/30/1999
Pegylated arginine deiminase TN= Hepacid	Treatment of hepatocellular carcinoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=03/26/1999
Pegylated arginine deiminase TN= Melanocid	Treatment of invasive malignant melanoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=04/12/1999
Polyethylene glycol-modified uricase TN= Zurase	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=09/14/1999
Recombinant human C1-esterase inhibitor TN=	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel, Belgium DD=02/23/1999
Recombinant human C1-esterase inhibitor TN=	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel, Belgium DD=02/23/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant human insulin-like growth factor-I/insulin -like growth factor binding protein-3 TN=	Treatment of major burns that require hospitalization.	Celtrix Pharmaceuticals, Inc. 3055 Patrick Henry Dr. Santa Clara, CA 95054 DD=06/15/1999
Recombinant human nerve growth factor TN=	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=04/16/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of solid organ transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Rifalazil TN=	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=04/13/1999
SCH 58500 TN=	Treatment of primary ovarian cancer.	Schering Corporation 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=04/12/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Sodium 1,3-propanedisulfonate TN=	Treatment of secondary amyloidosis.	Neurochem, Inc. 7220 Frederick Banting, Suite 100 Saint-Laurent, Quebec Canada H4S 2A1 DD=04/06/1999
Sodium dichloroacetate TN= Ceresine	Treatment of severe head injury.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=06/14/1999
Somatropin (rDNA origin) TN= Neutropin Depot	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=10/28/1999
Somatropin [rDNA] TN= Genotropin	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn 7000 Portage Rd. 0633-298-113 Kalamazoo, MI 49001 DD=07/06/1999
Synthetic human secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 1550 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic human secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Synthetic human secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic porcine secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Temoporfin TN= Foscan	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Scotia Pharmaceuticals Ltd. Scotia House, Castle Business Park Stirling Scotland FK9 4TZ DD=10/28/1999
Temozolomide TN= Temodar	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=10/05/1998 MA=08/11/1999

Orphan Product Designations and Approvals List
October 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Teriparatide TN= Parathar	Treatment of idiopathic osteoporosis.	Henri Beaufour Institute USA, Inc. 27 Maple St. Milford, MA 01757 DD=10/28/1999
Thalidomide TN= Thalomid	Treatment of Crohn's disease.	Celgene Corporation 7 Powder Horn Dr. Warren, NJ 07059 DD=04/06/1999
Tobramycin TN= Tobi	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=06/18/1999
Transgenic human alpha 1 antitrypsin TN=	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K. DD=05/19/1999
Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembryonic antigen IgG antibody TN= Cea-Cide	Treatment of ovarian carcinoma.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=08/03/1999

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO OCTOBER 1999 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 19TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

NP* NEW PRODUCT (MINT FLAVORED)

REFERENCES

NEW DOSING SCHEDULE

D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS

NEW INDICATION

I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C

I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER

I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN

I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN

I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)

I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)

I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY

I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION

I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES FOUR AND ABOVE

I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)

I-261 TREATMENT OF SOCIAL ANXIETY DISORDER

I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12

I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY

I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION

I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER

I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES

I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER-FOR CORTICOSTEROID-RESPONSIVE DERMATOSES

I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES

REFERENCES

MISCELLANEOUS EXCLUSIVITY CODES

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION

PATENT USE CODE

U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECITON IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN.
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN.
U-265	USE AS A LAXATIVE
U-266	OSTEOARTHRITIS
U-267	METHOD FOR PREVENTING HEARTBURN
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-270	METHOD FOR IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY, TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020482 004	ACARBOSE;PRECOSE				I-252	SEP 29, 2001
						I-253	SEP 29, 2001
	020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010	U-134		
			RE34440	MAR 31, 2010	U-275		
	020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010	U-134		
			RE34440	MAY 31, 2010	U-275		
>ADD>	020059 001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		
	020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA				I-262	JUN 02, 2002
	019621 001	ALBUTEROL SULFATE;VENTOLIN	4594359	JUN 10, 2003			
	020560 001	ALENDRONATE SODIUM;FOSAMAX				I-272	JUN 16, 2002
	020560 002	ALENDRONATE SODIUM;FOSAMAX				I-272	JUN 16, 2002
	020560 003	ALENDRONATE SODIUM;FOSAMAX				I-272	JUN 16, 2002
	020886 001	ALITRETINOIN;PANRETIN				ODE	FEB 02, 2006
						NCE	FEB 02, 2004
	020221 001	AMIFOSTINE;ETHYOL				ODE	JUN 24, 2006
>ADD>	020364 002	AMLODIPINE BESYLATE;LOTREL	4572909	JUL 31, 2006			
>ADD>	020364 003	AMLODIPINE BESYLATE;LOTREL	4572909	JUL 31, 2006			
>ADD>	020364 004	AMLODIPINE BESYLATE;LOTREL	4572909	JUL 31, 2006			
	020508 001	AMMONIUM LACTATE;LAC-HYDRIN				PED	FEB 29, 2000
	021007 001	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021007 002	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021039 001	AMPRENAVIR;AGENERASE	5585397	DEC 17, 2013		NCE	APR 15, 2004
	020702 001	ATORVASTATIN CALCIUM;LIPITOR	5969156	JUL 08, 2016			
	020702 002	ATORVASTATIN CALCIUM;LIPITOR	5969156	JUL 08, 2016			
	020702 003	ATORVASTATIN CALCIUM;LIPITOR	5969156	JUL 08, 2016			
	020500 001	ATOVAQUONE;MEPRON				ODE	JAN 05, 2006
						I-255	JAN 05, 2002
	020746 001	BUDESONIDE;RHINOCORT				NDF	OCT 01, 2002
	020746 002	BUDESONIDE;RHINOCORT				NDF	OCT 01, 2002
	020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			
	020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			
	020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
			5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
	020793 001	CAFFEINE CITRATE;CAFCIT				NE	SEP 21, 2002
	020313 002	CALCITONIN, SALMON;MIACALCIN	5759565	JUN 02, 2015			
	020896 001	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271		
			4966891	NOV 08, 2008	U-272		
	020896 002	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271		
			4966891	NOV 08, 2008	U-272		
	020712 001	CARBAMAZEPINE;CARBATROL	5912013	JUN 15, 2016	U-277		
	020712 002	CARBAMAZEPINE;CARBATROL	5912013	JUN 15, 2016	U-277		
	020998 001	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			
	020998 002	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NS	MAY 24, 2002
			5177080	NOV 26, 2011			
	020638 001	CIDOFOVIR;VISTIDE	5142051	JUN 26, 2010			
	020863 001	CILOSTAZOL;PLETAL	4277479	AUG 29, 2000		NCE	JAN 15, 2004
	020863 002	CILOSTAZOL;PLETAL	4277479	AUG 29, 2000		NCE	JAN 15, 2004
	019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
			5286754	FEB 15, 2011			
	020767 001	CISAPRIDE MONOHYDRATE;PROPULSID QUICKSOLV	5648093	JUL 15, 2014			
->ADD->	020463 001	CROMOLYN SODIUM;NASALCROM				PED	JUL 03, 2000
	021041 001	CYTARABINE;DEPOCYT				ODE	APR 01, 2006
						NP	APR 01, 2002
	020287 001	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 003	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 004	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	017922 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 003	DESMOPRESSIN ACETATE;DDAVP (NEEDS NO REFRIGERATION)	5763407	JUN 29, 2013			
	074752 001	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 20, 1999
	074752 003	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 20, 1999
	074752 004	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 20, 1999
	020449 001	DOCETAXEL;TAXOTERE	4814470	MAY 14, 2010			
			5438072	NOV 22, 2013			
			5698582	JUL 03, 2012			
			5714512	JUL 03, 2012			
	020931 001	DOFETILIDE;TIKOSYN				NCE	OCT 01, 2004
	020931 002	DOFETILIDE;TIKOSYN				NCE	OCT 01, 2004
	020931 003	DOFETILIDE;TIKOSYN				NCE	OCT 01, 2004
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008			
			4619939	OCT 28, 2003			
	020862 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-278	NCE	JUN 09, 2004
			5707980	FEB 11, 2117	U-278		
	050718 001	DOXORUBICIN HYDROCHLORIDE;DOXIL				ODE	JUN 28, 2006
	020972 001	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256		
			5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
	020972 002	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256		
			5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
	020972 003	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
			5811423	AUG 07, 2012	U-256		
->ADD->	020796 001	ENTACAPONE;COMTAN				NCE	OCT 19, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	050778 001	EPIRUBICIN HYDROCHLORIDE;ELLENCE				ODE	SEP 15, 2006
	020375 001	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 002	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 003	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 004	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
	020908 001	ESTRADIOL;VAGIFEM				NP	MAR 26, 2002
	020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NP	MAR 24, 2002
	020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NP	MAR 24, 2002
>ADD>	010971 005	ESTROGENS, CONJUGATED;PMB 200	5210081	FEB 26, 2012			
>ADD>	010971 003	ESTROGENS, CONJUGATED;PMB 400	5210081	FEB 26, 2012			
>ADD>	004782 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
>ADD>	004782 002	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
>ADD>	004782 003	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
>ADD>	004782 004	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
>ADD>	004782 005	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
>ADD>	010402 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
>ADD>	020216 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
>ADD>	020303 002	ESTROGENS, CONJUGATED;PREMPHASE (PREMARIN;CYCRIN 14/14)	5210081	FEB 26, 2012			
>ADD>	020527 002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	5210081	FEB 26, 2012			
>ADD>	020303 001	ESTROGENS, CONJUGATED;PREMPRO (PREMARIN;CYCRIN 14/14)	5210081	FEB 26, 2012			
>ADD>			RE36247	MAY 02, 2006	U-284		
>ADD>	020527 001	ESTROGENS, CONJUGATED;PREMPRO 14/14	5210081	FEB 26, 2012			
			RE36247	MAY 02, 2006			
>ADD>	020527 003	ESTROGENS, CONJUGATED;PREMPRO 14/14	5210081	FEB 26, 2012			
			4826831	MAY 02, 2006			
			5547948	JAN 17, 2015			
			RE36247	MAY 02, 2006			
	021065 001	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
	021065 002	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
	021065 003	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
	020584 003	ETODOLAC;LODINE XL	4966768	OCT 30, 2007			
>ADD>	020753 001	EXEMESTANE;AROMASIN	4808616	JUL 07, 2006		NCE	OCT 21, 2004
>ADD>			4904650	JUL 07, 2006		ODE	OCT 21, 2006
	020363 001	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
	020363 003	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
	020325 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-267		
	020801 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015			
			5854267	DEC 29, 2015	U-267		
			5075114	DEC 24, 2008			
	019304 002	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
>ADD>	019304 003	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
>ADD>	019304 004	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
	020747 001	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 002	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 003	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 004	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 005	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 006	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020955 001	FERRIC SODIUM GLUCONATE;FERRLECIT				NCE	FEB 18, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5855912	FEB 28, 2015			
			5738872	FEB 28, 2015			
	020788 001	FINASTERIDE;PROPECIA	5571817	NOV 05, 2013	U-259		
			5886184	NOV 19, 2012			
	020180 001	FINASTERIDE;PROSCAR	4760071	JUN 19, 2006	U-262		
			5886184	NOV 19, 2012			
			4377584	MAR 22, 2000	U-261		
			5942519	OCT 23, 2018	U-280		
	019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-265	AUG 18, 2002
>ADD>	018936 003	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
>ADD>			4626549	DEC 02, 2003	U-154		
>ADD>			4626549	DEC 02, 2003	U-84		
>ADD>	018936 004	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
>ADD>			4626549	DEC 02, 2003	U-154		
>ADD>			4626549	DEC 02, 2003	U-84		
	020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
					U-154		
	020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
			4626549	DEC 02, 2003	U-154		
			4314081	FEB 02, 2001			
	020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
			4626549	DEC 02, 2003	U-154		
			4314081	FEB 02, 2001			
	019958 001	FLUTICASONE PROPIONATE;CUTIVATE				I-267	JUN 17, 2002
	020121 001	FLUTICASONE PROPIONATE;FLONASE				I-258	DEC 11, 2001
>ADD>	020582 001	FOLLITROPIN ALFA/BETA;FOLLISTIM	5767251	JUN 16, 2015			
>ADD>	020582 002	FOLLITROPIN ALFA/BETA;FOLLISTIM	5767251	JUN 16, 2015			
	020882 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		
	020882 002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		
	021057 001	GANIRELIX ACETATE;ANTAGON	4801577	FEB 05, 2007		NCE	JUL 29, 2004
			5767082	JUN 16, 2015			
	020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010			
	020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010			
	020496 001	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
	020496 002	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
	020496 003	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
	020305 001	GRANISETRON HYDROCHLORIDE;KYTRIL				I-264	JUL 27, 2002
	020305 002	GRANISETRON HYDROCHLORIDE;KYTRIL				I-264	JUL 27, 2002
	020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
	020491 001	IBUTILIDE FUMARATE;CORVERT				D-50	MAY 13, 2002
	020723 001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2009	U-172		
	021028 001	INSULIN HUMAN;VELOSULIN BR				NP	JUL 19, 2002
	020083 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020657 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020966 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
			4267179	JUN 23, 2000			
	021066 001	KETOTIFEN FUMARATE;ZADITOR				NCE	JUL 02, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020564 001	LAMIVUDINE;EPIVIR	5905082	MAY 18, 2016			
	021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
			5532246	JUL 02, 2013	U-250		
	021004 001	LAMIVUDINE;EPIVIR-HBV	5905082	MAY 18, 2016			
			5047407	FEB 08, 2009		I-257	DEC 08, 2001
			5532246	JUL 02, 2013	U-250		
	020764 001	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 002	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 003	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020406 001	LANSOPRAZOLE;PREVACID				M-1	JUL 06, 2002
	020406 002	LANSOPRAZOLE;PREVACID				M-1	JUL 06, 2002
	020597 001	LATANOPROST;XALATAN	5296504	MAR 22, 2011	U-260		
			5422368	MAR 22, 2011	U-260		
			4599353	JUL 28, 2006	U-260		
			4652441	NOV 01, 2004			
	020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4				NP	MAR 25, 2002
	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX				NP	MAR 25, 2002
	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX					
>ADD>	020035 001	LEVAMISOLE HYDROCHLORIDE;ERGAMISOL	4584305	JUN 18, 2004	U-42		
	020997 001	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
	020997 002	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
	020997 003	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
	021045 001	LEVONORGESTREL;PLAN B				NP	JUL 28, 2002
	019941 001	LIDOCAINE;EMLA				I-260	MAR 11, 2002
	020612 001	LIDOCAINE;LIDODERM				ODE	MAR 19, 2006
	019777 006	LISINOPRIL;ZESTRIL	4374829	DEC 30, 2001			
	019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	021047 001	LUTEINIZING HORMONE;REPRONEX				NP	AUG 27, 2002
	021047 002	LUTEINIZING HORMONE;REPRONEX				NP	AUG 27, 2002
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020969 001	METHOXSALEN;UVADEX	4845075	APR 11, 2009		NP	FEB 25, 2002
			5036102	JUL 30, 2008	U-273		
			4999375	MAR 12, 2008			
	020968 001	MICONAZOLE NITRATE;MONISTAT DUAL- PAK	5514698	MAR 21, 2014		NP	JUN 30, 2002
	020682 001	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020682 002	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020682 003	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
>ADD>	019436 001	MILRINONE LACTATE;PRIMACOR	4313951	NOV 26, 2001			
>ADD>	020343 001	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
>ADD>	020343 002	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
>ADD>	020343 003	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
	020717 001	MODAFINIL;PROVIGIL	4177290	MAR 09, 1999			
			5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		
	020717 002	MODAFINIL;PROVIGIL	4177290	MAR 09, 1999			
			5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020933 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011			
	018612 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020066 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020385 001	NICOTINE;NICOTROL					
>ADD>	020714 001	NICOTINE;NICOTROL	5656255	AUG 12, 2014			
>ADD>			5400808	JUN 08, 2010			
>ADD>			4917120	APR 17, 2007			
>ADD>			4800903	JAN 31, 2006			
>ADD>			4793366	DEC 27, 2005			
>ADD>			5167242	JUN 08, 2010			
>ADD>	018705 002	NITROGLYCERIN;NITROLINGUAL PUMPSPRAY	5501236	JUN 08, 2010			
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5186925	FEB 16, 2010			
			5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			
	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			
	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			
	020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN				I-269	AUG 27, 2002
	020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN				I-269	AUG 27, 2002
>ADD>	020766 001	ORLISTAT;XENICAL				NCE	APR 23, 2004
>ADD>	021087 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	4598089	JUN 18, 2004		NCE	OCT 27, 2004
>ADD>			5763483	DEC 27, 2016			
>ADD>			5866601	FEB 02, 2016			
			5952375	FEB 02, 2016			
	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	4783337	SEP 16, 2003		NP	DEC 16, 2001
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			5840754	MAY 22, 2015			
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	5912268	MAY 22, 2015			
			5840754	MAY 22, 2015		NP	DEC 16, 2001
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
			5912268	MAY 22, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	5912268	MAY 22, 2015		NP	DEC 16, 2001
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
			5840754	MAY 22, 2015			
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
	020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020262 001	PACLITAXEL;TAXOL				I-270	OCT 25, 2002
>ADD>	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	5789449	JAN 06, 2009	U-285	I-261	MAY 17, 2002
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
>ADD>	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	5789449	JAN 06, 2009	U-285	I-261	MAY 17, 2002
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
>ADD>	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	5789449	JAN 06, 2009	U-285	I-261	MAY 17, 2002
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
>ADD>	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	5789449	JAN 06, 2009	U-285	I-261	MAY 17, 2002
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
>ADD>	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	5789449	JAN 06, 2009	U-285	I-261	MAY 17, 2002
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
>ADD>	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	5789449	JAN 06, 2009	U-285		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
>ADD>	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5789449	JAN 06, 2009	U-285		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
>ADD>	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5789449	JAN 06, 2009	U-285		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
>ADD>	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5789449	JAN 06, 2009	U-285		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
>ADD>	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5789449	JAN 06, 2009	U-285		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
>ADD>	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5789449	JAN 06, 2009	U-286	NDF	FEB 16, 2002
			5872132	MAY 19, 2015			
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5789449	JAN 06, 2009	U-286	NDF	FEB 16, 2002
			5872132	MAY 19, 2015			
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			
	021079 001	PEMIROLAST POTASSIUM;ALAMAST	5034230	DEC 23, 2008	U-184	PED	MAR 24, 2005
			5034230*PED	JUN 23, 2009	U-184	NCE	SEP 24, 2004
	021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
			4687777	JAN 17, 2006			
	021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
			4687777	JAN 17, 2006			
	021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
			4687777	JAN 17, 2006			
	020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	5710183	JUL 14, 2015	U-265	NP	FEB 18, 2002
>ADD>	020744 001	PORACTANT ALPHA;CURASURF				NCE	NOV 18, 2004
>ADD>	020667 001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
>ADD>	020667 002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
>ADD>	020667 003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
>ADD>	020667 004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
>ADD>	020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	MAR 25, 2011			
>ADD>	020667 006	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
	019627 002	PROPOFOL;DIPRIVAN	5714520	MAR 22, 2015			
			5714520*PED	SEP 22, 2015			
			5731355	MAR 22, 2015	U-217		
			5731355*PED	SEP 22, 2015	U-217		
			5731356	MAR 22, 2015	U-218		
			5731356*PED	SEP 22, 2015	U-218		
			5908869	MAR 22, 2015	U-270		
			5908869*PED	SEP 22, 2015	U-270		
	075102 001	PROPOFOL;PROPOFOL				PC	OCT 17, 1999
	020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
	020973 002	RABEPRAZOLE SODIUM;ACIPHEX				NCE	AUG 19, 2004
>ADD>	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	5466810	JUN 10, 2014		I-271	SEP 30, 2002
>ADD>			5514826	JUN 07, 2015			
>ADD>			5569772	JUN 07, 2015			
>ADD>			5629425	SEP 19, 2014			
>ADD>			5659087	JUN 07, 2015			
>ADD>			5710285	MAR 31, 2015			
>ADD>			5731327	MAR 24, 2015			
>ADD>			5731342	JAN 27, 2017			
>ADD>			5747510	MAR 02, 2014			
>ADD>			5808061	MAR 31, 2014			
>ADD>			5811120	MAR 02, 2014			
>ADD>			5843984	APR 14, 2017			
>ADD>			5972383	MAR 02, 2014	U-287		
	075094 001	RANITIDINE HYDROCHLORIDE;RANITIDINE HCL				PC	JAN 14, 2000
	020984 001	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
	020984 002	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020903 001	RIBAVIRIN;REBETOL	5914128	DEC 22, 2017			
	020272 007	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37	OCT 17, 2000
			4804663	DEC 29, 2007	U-90		
	020272 008	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	D-37	OCT 17, 2000
			5158952	OCT 27, 2009	U-90		
	020680 001	RITONAVIR;NORVIR	5948436	SEP 13, 2013			
	020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5457895	OCT 01, 2013			
	020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5457895	OCT 01, 2013			
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
>ADD>	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152		
>ADD>	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152		
>ADD>	019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152		
>ADD>	019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152		
>ADD>	019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152		
	019766 001	SIMVASTATIN;ZOCOR				I-273	AUG 05, 2002
	019766 002	SIMVASTATIN;ZOCOR				I-273	AUG 05, 2002
	019766 003	SIMVASTATIN;ZOCOR				I-273	AUG 05, 2002
	019766 004	SIMVASTATIN;ZOCOR				I-273	AUG 05, 2002
	019766 005	SIMVASTATIN;ZOCOR				I-273	AUG 05, 2002
	021083 001	SIROLIMUS;RAPAMUNE				NCE	SEP 15, 2004
	019640 005	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
						ODE	DEC 30, 2003
	019640 006	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
						ODE	DEC 30, 2003
	019640 007	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
						ODE	DEC 30, 2003
>ADD>	020412 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
>ADD>	020412 002	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
>ADD>	020412 003	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
>ADD>	020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
>ADD>	020412 005	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
>ADD>	020413 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008			
	021012 001	TECHNETIUM TC-99M DEPREOTIDE;NEO TECT KIT				NCE	AUG 03, 2004
	021029 001	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 002	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 003	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021029 004	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	074823 001	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
	074823 002	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
	074823 003	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
	074823 004	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
	020539 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-281		
	020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL				NCE	DEC 30, 1999
	020980 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-73	NCE	DEC 30, 1999
	020846 001	TERBINAFINE;LAMISIL	4755534	DEC 30, 2006	U-73		
	019762 001	TESTOSTERONE;TESTODERM				NP	APR 29, 2001
	019762 002	TESTOSTERONE;TESTODERM				NCE	DEC 30, 1999
	020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5840327	AUG 15, 2016			
			5840327	AUG 15, 2016			
>ADD>	020707 001	TILUDRONATE DISODIUM;SKELID	5010090	OCT 07, 2008			
>ADD>	020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5354760	MAR 24, 2012		NCE	SEP 30, 2002
>ADD>			4876248	JAN 30, 2010			
			5965581	OCT 23, 2016			
			5972967	OCT 23, 2016			
>ADD>	020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230		
>ADD>			5880136	SEP 27, 2010	U-254		
			5965581	OCT 23, 2016			
			5972967	OCT 23, 2016			
			5292756	MAY 14, 2012	U-230		
			5880136	SEP 27, 2010	U-254		
	020505 001	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
						I-274	OCT 01, 2002
	020505 002	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
						I-274	OCT 01, 2002
	020505 003	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
						I-274	OCT 01, 2002
	020505 004	TOPIRAMATE;TOPAMAX				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020505 005	TOPIRAMATE;TOPAMAX				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020505 006	TOPIRAMATE;TOPAMAX				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020671 001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN				I-274	OCT 01, 2002
>ADD>	020719 001	TROGLITAZONE;PRELAY				I-266	JUL 23, 2002
>ADD>	020719 002	TROGLITAZONE;PRELAY				I-256	NOV 30, 2001
>ADD>	020719 003	TROGLITAZONE;PRELAY				I-275	JUN 16, 2002
>ADD>	020720 001	TROGLITAZONE;REZULIN				I-275	JUN 16, 2002
>ADD>	020720 002	TROGLITAZONE;REZULIN				I-275	JUN 16, 2002
						I-276	JUN 16, 2002
						I-276	JUN 16, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020720 003	TROGLITAZONE;REZULIN					
	020759 001	TROVAFLOXACIN MESYLATE;TROVAN				I-276	JUN 16, 2002
			5164402	NOV 17, 2009	U-282		
	020759 002	TROVAFLOXACIN MESYLATE;TROVAN	5763454	JUN 15, 2015	U-282		
			5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		
	020900 001	UREA, C-13;PYLORI-CHEK BREATH TEST				NCE	SEP 17, 2001
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	019614 004	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007			
	020943 001	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020943 002	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020943 003	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020547 001	ZAFIRLUKAST;ACCOLATE				I-268	SEP 17, 2002
	020859 001	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
	020859 002	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
	021036 001	ZANAMIVIR;RELENZA	D379506	MAY 27, 2011		NCE	JUL 26, 2004
			4778054	OCT 18, 2005			
			4811731	JUL 29, 2006			
			5035237	JUL 30, 2008			
			5360817	NOV 01, 2011			
			5648379	JUL 15, 2014	U-274		
			4627432	DEC 09, 2003			

New 20th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8312

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $90.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

( ) Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

Thank you for your order!

(Authorizing Signature)

(10/98)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

Approved drug products with therapeutic equivalence